SCHOOL OF SOCIAL SCIENCES

MSc in Innovation Management and Entrepreneurship – (IME)

Postgraduate Dissertation

"Business Planning and Opportunity Exploitation in the Pharmaceutical Industry: The Case of Innovative Drug Products"

Eleftherios G. Doukas

Supervisor: Panagiota Athanasia Sapouna

Patras, Greece, June 2026

"Business Planning and Opportunity Exploitation in the Pharmaceutical Industry: The Case of Innovative Drug Products"

Eleftherios G. Doukas

Supervising Committee

Supervisor:

Panagiota Athanasia Sapouna

Assistant Professor

Department of Economics - University of Piraeus

Co-Supervisor:

Ioanna Deligianni

Associate Professor

Department of Management Science and Technology - Athens University of Economics and Business (AUEB)

Patras, Greece, June, 2026

Abstract

The biopharmaceutical industry is currently navigating a profound structural and economic paradigm shift. Driven by increased research and development costs, application of strict regulatory rules and market access limitations, and the emergence of strict Environmental, Social, and Governance (ESG) requirements, the traditional, often coincidental model of mass-market drug discovery and commercial launching is considered no longer commercially viable.

This dissertation critically evaluates how contemporary biopharmaceutical firms engineer, exploit, and sustain commercial opportunities in this highly complex environment. Structured as a secondary-research, literature-based sectoral analysis, the study investigates macro-level innovation trends across the lifecycle of innovative drug products. By substantiating the analysis in established innovation and entrepreneurship theories, the research identifies a fundamental transition in opportunity identification. Specifically, it highlights the shift from passive random discoveries to the systematic operationalization of Kirzner's Entrepreneurial Alertness. To strategically exploit these opportunities, a recent tendency is observed where firms are increasingly transforming into hybrid technology-biology organizations. Through the lens of Chesbrough's Open Innovation, the study demonstrates how integrating computational capital approaches, including Artificial Intelligence, algorithmic networks, as well as in silico clinical trials, effectively mitigating potential risks in highly capitalized assets and accelerates developmental timelines.

Furthermore, by applying Teece's Business Model and dynamic capabilities frameworks, the study analyzes how firms navigate late-stage commercialization limitations, such as patent cliffs and global affordability ceilings, through multi-modal lifecycle management, strategic formulation switches, and the adoption of outcome-based risk-sharing agreements. Looking towards the 2030 horizon, the dissertation highlights a decisive industry shift on the direction of multi-functional architectures, individualized genetic medicines, and decentralized manufacturing ecosystems.

Ultimately, rather than exclusively describing existing industry practices, this research synthesizes these theoretical foundations to offer a new conceptual framework for modern pharmaceutical commercialization. It concludes that the intrinsic scientific novelty of an active pharmaceutical ingredient is only a foundational prerequisite. Contemporary value

creation in pharmaceutical industry requires the presence of three core competencies: i. the entrepreneurial alertness to identify latent opportunities in clinical procedures, ii. the technological capability to construct AI-driven exploitation platforms for dedicated use in pharmaceutical industry and iii. the ethical foresight to ensure supply chain sustainability and equitable access.

Commercial success is now fundamentally defined by the speed, precision, and systemic integrity of the strategic pathway engineered to deliver the innovative drug product to the patient.

Keywords

Biopharmaceutical Industry, Innovative pharmaceutical products, Innovation Management, Opportunity Exploitation, Computational Capital, Lifecycle Management.

"Επιχειρηματικός Σχεδιασμός και Αξιοποίηση Ευκαιριών στη Φαρμακευτική Βιομηχανία: Η Περίπτωση των Καινοτόμων Φαρμακευτικών Προϊόντων"

Ελευθέριος Γ. Δούκας

Περίληψη

Η βιο-φαρμακευτική βιομηχανία διέρχεται επί του παρόντος μια βαθιά δομική και οικονομική κρίση. Συχνά ως αποτέλεσμα του αυξημένου κόστους έρευνας και ανάπτυξης (R&D), την εφαρμογή αυστηρών κανονιστικών διαδικασιών και περιορισμών πρόσβασης στην αγορά, καθώς και από την εμφάνιση αυστηρών απαιτήσεων Περιβαλλοντικής, Κοινωνικής και Εταιρικής Διακυβέρνησης (ESG), το παραδοσιακό, συχνά συμπτωματικό μοντέλο ανακάλυψης και εμπορικής αξιοποίησης φαρμάκων ευρείας κατανάλωσης, δεν είναι πλέον εμπορικά βιώσιμο.

Η παρούσα διπλωματική εργασία αξιολογεί με κριτικό τρόπο τις μεθοδολογίες με τις οποίες οι σύγχρονες βιο-φαρμακευτικές εταιρείες σχεδιάζουν, αξιοποιούν και διατηρούν τις εμπορικές ευκαιρίες που αναπτύσσονται σε αυτό το εξαιρετικά περίπλοκο περιβάλλον. Δομημένη ως μια δευτερογενής και βασισμένη στη βιβλιογραφική ανάλυση, η μελέτη διερευνά τις μακροοικονομικές τάσεις εφαρμογής της καινοτομίας σε ολόκληρο τον κύκλο ζωής των καινοτόμων φαρμακευτικών προϊόντων.

Βασίζοντας την ανάλυση σε καθιερωμένες θεωρίες καινοτομίας και επιχειρηματικότητας, η έρευνα εντοπίζει μια θεμελιώδη μετάβαση στον εντοπισμό ευκαιριών. Συγκεκριμένα, υπογραμμίζει τη μετάβαση από τις παθητικές και συχνά τυχαίες ανακαλύψεις φαρμακευτικών προϊόντων στη συστηματική επιχειρησιακή εφαρμογή της «Επιχειρηματικής Εγρήγορσης» (Entrepreneurial Alertness) του Kirzner. Για τη στρατηγική αξιοποίηση αυτών των ευκαιριών, οι εταιρείες μετασχηματίζονται όλο και περισσότερο σε υβριδικούς οργανισμούς τεχνολογίας-βιολογίας (tech-bio).

Μέσα από το πρίσμα της «Ανοικτής Καινοτομίας» (Open Innovation) του Chesbrough, η μελέτη καταδεικνύει πώς η ενσωμάτωση προσεγγίσεων υπολογιστικού κεφαλαίου,

συμπεριλαμβανομένης της Τεχνητής Νοημοσύνης (AI), των αλγοριθμικών δικτύων και εικονικών in silico κλινικών δοκιμών, μετριάζει αποτελεσματικά τους κινδύνους σχετικά με την αξιοποίηση περιουσιακών στοιχείων υψηλής κεφαλαιοποίησης και επιταχύνει τα χρονοδιαγράμματα ανάπτυξης των σκευασμάτων.

Επιπλέον, εφαρμόζοντας τα πλαίσια Επιχειρηματικών Μοντέλων (Business Models) του Teece, η μελέτη αναλύει πώς οι επιχειρήσεις διαχειρίζονται περιορισμούς εμπορευματοποίησης όπως η λήξη των πατεντών και τα παγκόσμια όρια προσβασιμότητας, μέσω πολυτροπικής διαχείρισης, στρατηγικών αλλαγών στη σύνθεση και συμφωνιών επιμερισμού του κινδύνου

Με βάση τα δεδομένα της τρέχουσας δεκαετίας, εντοπίζεται μια αποφασιστική στροφή του κλάδου με την υιοθέτηση πολυλειτουργικών αρχιτεκτονικών, εξατομικευμένων θεραπειών και αποκεντρωμένων οικοσυστήματα παραγωγής. Εν τέλει, η έρευνα καταλήγει στο συμπέρασμα ότι η δημιουργία ευκαιριών στο σύγχρονο βιο-φαρμακευτικό περιβάλλον απαιτεί την παρουσία τριών βασικών προυποθέσεων: i. επιχειρηματική εγρήγορση για τον εντοπισμό λανθανουσών ευκαιριών, ii. τεχνολογική ικανότητα συνδυασμένη με την κατασκευή εφαρμογών τεχνητής νοημοσύνης (AI) και iii. Εταιρική προνοητικότητα για τη διασφάλιση της βιωσιμότητας της εφοδιαστικής αλυσίδας και της ισότιμης πρόσβασης του καινοτόμου σκευάσματος σε παγκόσμια βάση.

Λέξεις – Κλειδιά

Βιο-φαρμακευτική Βιομηχανία, Καινοτόμα Φαρμακευτικά Προϊόντα, Διαχείριση Καινοτομίας, Αξιοποίηση Ευκαιριών, Υπολογιστικό Κεφάλαιο, Διαχείριση Κύκλου Ζωής.

Table of Contents

List of Figures

List of Tables

List of Abbreviations & Acronyms

A–C

- **AEDs:** Anti-Epileptic Drugs
- **AI:** Artificial Intelligence
- **ALCOA+:** Attributable, Legible, Contemporaneous, Original, and Accurate
- **ALL:** Acute Lymphoblastic Leukemia
- **API:** Active Pharmaceutical Ingredient
- **ARIA:** Amyloid-Related Imaging Abnormalities
- **ATMP:** Advanced Therapy Medicinal Product
- **BiTE:** Bispecific T-cell Engager
- **BMI:** Business Model Innovation
- **BTD:** Breakthrough Therapy Designation
- **CapEx:** Capital Expenditure
- **CAR-T:** Chimeric Antigen Receptor T-cell
- **CEDDs:** Centers of Excellence for Drug Discovery
- **CF:** Cystic Fibrosis
- **CGTs:** Cell and Gene Therapies
- **CKD:** Chronic Kidney Disease
- **CM:** Continuous Manufacturing
- **CML:** Chronic Myeloid Leukemia
- **COGS:** Cost of Goods Sold
- **CS3D:** Corporate Sustainability Due Diligence Directive
- **CSF:** Cerebrospinal Fluid
- **CSR:** Corporate Social Responsibility
- **CSRs:** Clinical Study Reports
- **CVAs:** Collaborative Value Assessments

D–F

- **DCF:** Discounted Cash Flow
- **DLTs:** Distributed Ledger Technologies
- **DPPs:** Digital Product Passports

- **ED:** Erectile Dysfunction
- **EFPIA:** European Federation of Pharmaceutical Industries and Associations
- **EHRs:** Electronic Health Records
- **EMA:** European Medicines Agency
- **eNPV:** Expected Net Present Value
- **ERA:** Environmental Risk Assessment
- **ESG:** Environmental, Social, and Governance
- **EU:** European Union
- **FAIR:** Findable, Accessible, Interoperable, and Reusable
- **FDA:** Food and Drug Administration (United States)

G–I

- **GIST:** Gastrointestinal Stromal Tumors
- **GLP-1:** Glucagon-Like Peptide-1
- **GSK:** GlaxoSmithKline
- **GxP:** Good Laboratory and Manufacturing Practices
- **HEOR:** Health Economics and Outcomes Research
- **HTA:** Health Technology Assessment
- **HTAR:** Health Technology Assessment Regulation
- **IBP:** Integrated Business Planning
- **IEPs:** Integrated Evidence Plans
- **IPF:** Idiopathic Pulmonary Fibrosis
- **IRP:** International Reference Pricing
- **IRR:** Internal Rate of Return
- **ISCTs:** *In Silico* Clinical Trials
- **IV:** Intravenous

J–M

- **JCA:** Joint Clinical Assessment
- **LAIs:** Long-Acting Injectables
- **LIMS:** Laboratory Information Management Systems
- **LLM:** Large Language Model

- **LNPs:** Lipid Nanoparticles
- **LOE:** Loss of Exclusivity
- **MGDs:** Molecular Glue Degraders
- **MIDD:** Model-Informed Drug Development
- **MRI:** Magnetic Resonance Imaging
- **MS:** Multiple Sclerosis

N–P

- **NDAs:** New Drug Applications
- **NHS:** National Health Service (UK)
- **NICE:** National Institute for Health and Care Excellence (UK)
- **NMEs:** New Molecular Entities
- **NPV:** Net Present Value
- **OBRSAs:** Outcome-Based Risk-Sharing Agreements
- **ODA:** Orphan Drug Act (US)
- **PDE5:** Phosphodiesterase Type 5
- **PET:** Positron Emission Tomography
- **PICO:** Population, Intervention, Comparator, and Outcomes
- **PNH:** Paroxysmal Nocturnal Hemoglobinuria
- **PRIME:** Priority Medicines
- **PRV:** Priority Review Voucher
- **PTRS:** Probability of Technical and Regulatory Success

Q–S

- **QALYs:** Quality-Adjusted Life Years
- **QuEEN:** Quantitative and Engineered Elimination of Neosubstrates
- **R&D:** Research and Development
- **RBV:** Resource-Based View
- **RCT:** Randomized Controlled Trial
- **RLTs:** Radioligand Therapies
- **RWD:** Real-World Data
- **RWE:** Real-World Evidence

- **SC:** Subcutaneous
- **SCAs:** Synthetic Control Arms
- **SMA:** Spinal Muscular Atrophy
- **SoC:** Standard of Care

T–Z

- **T2DM:** Type 2 Diabetes Mellitus
- **TBDD:** Target-Based Drug Discovery
- **TKIs:** Tyrosine Kinase Inhibitors
- **TPD:** Targeted Protein Degradation
- **TRK:** Tropomyosin Receptor Kinases
- **TTM:** Time-to-Market
- **VBCs:** Value-Based Contracts
- **WACC:** Weighted Average Cost of Capital
- **XAI:** Explainable AI

Introduction

Background and Problem Statement

The biopharmaceutical industry is currently navigating a profound structural and economic paradigm shift. Historically, pharmaceutical value creation was heavily reliant on the mass-market "blockbuster" model, driven by serendipitous phenotypic discovery and relatively straightforward clinical pathways. However, the contemporary landscape is defined by an existential innovation-cost paradox, formally characterized in pharmacoeconomic literature as "Eroom's Law" (Scannell et al., 2012). Despite exponential advancements in genomic sciences and high-throughput chemistry, the efficiency of research and development (R&D) has structurally collapsed, driving the capitalized cost of bringing a single novel molecule to market to approximately $2.6 billion (DiMasi, Grabowski, & Hansen, 2016).

This systemic productivity crisis is compounded by an increasingly hostile commercialization environment. Modern pharmaceutical assets face unprecedented evidentiary barriers from regulatory bodies and intense pricing pressures governed by stringent Health Technology Assessments (HTA). A prominent example is the implementation of the EU Joint Clinical Assessments (JCAs), which support member states' national HTA processes by providing a centralized, scientific analysis of clinical evidence regarding the relative effects of health technologies on patient outcomes (Main, Schäfer, & Kanavos, 2025). It must be highlighted that similar rigorous evaluation mechanisms have been adopted by various health authorities worldwide. These barriers have resulted in a significant reduction in the value proposition of traditional pharmaceutical products, leading to severe revenue erosion driven by the "patent cliffs" and Loss of Exclusivity (LOE) phenomena commonly observed in the industry (Song & Lee, 2016).

Furthermore, Environmental, Social, and Governance (ESG) criteria have rapidly transitioned from voluntary corporate initiatives into strict legal mandates that directly dictate market access (Eccles, Ioannou, & Serafeim, 2014; Pharma Focus Europe, 2026).

Consequently, various health authorities have consecutively proposed and implemented the strictest environmental regulations as absolute prerequisites for market entry.

As a result, scientific knowledge, specialization, experience, and chemical novelty are no longer sufficient to guarantee the commercial success and viability of a novel pharmaceutical product. The traditional "random walk" of drug discovery is officially obsolete (Swinney & Anthony, 2011), forcing a fundamental realignment in how pharmaceutical business planners conceptualize, evaluate, and capture value (Teece, 2010).

Purpose of the Dissertation

The primary purpose of this dissertation is to critically evaluate how novel business planning frameworks have evolved to identify, develop, exploit, and sustain commercial opportunities within the modern biopharmaceutical industry. To achieve this, the dissertation is explicitly framed around the overarching meta-framework of Dynamic Capabilities (Teece, 2007).

Furthermore, to demonstrate analytical rigor, this study utilizes an integrative synthesis methodology. By combining disconnected literature streams,such as pharmacoeconomics, dynamic capabilities, and digital transformation, this approach builds a new, unified conceptual model mapped directly against the pharmaceutical product lifecycle. The adoption of this holistic approach, allows the study to expand beyond the strict chemical performance of a novel molecular structure as it systematically investigates the competitive advantages, value propositions, and the highly complex strategic, digital, regulatory, and market access pathways engineered to deliver the pharmaceutical product to the patient.

Aims and Objectives

To comprehensively assess this multidimensional transition, this dissertation establishes the following specific aims:

1. To analyze the evolution of Opportunity Identification: The study examines the shift from serendipitous discovery to systematic "Entrepreneurial Alertness" (Kirzner, 1973; Tang, Kacmar, & Busenitz, 2012). It aims to deconstruct the pharmacoeconomics of the

"Orphan Drug Paradox" and evaluate how Integrated Business Planning (IBP) and "Fail-Fast" financial gating are utilized to confront the Eroom's Law principles.

2. To investigate the mechanisms of Strategic Exploitation: The research explores how externalization and Open Innovation (Chesbrough, 2003) are operationalized in the modern era. Specifically, it aims to assess the integration of "Computational Capital" (Iansiti & Lakhani, 2020), including Artificial Intelligence, algorithmic networks, and in silico assessments, as primary levers for reducing clinical trials complexity or even necessity and the need for exposure of volunteers to unknown substances during the clinical studies.

3. To evaluate systemic barriers to commercialization and lifecycle resilience: The dissertation investigates how modern pharmaceutical firms navigate late-stage existential threats, specifically the risk that a successful development and regulatory approval may still be followed by limited commercial viability. It aims to analyze "Multi-Modal Lifecycle Management" and "Strategic Switches" (Song & Lee, 2016) to mitigate patent cliffs, while also examining the transition toward Outcome-Based Risk-Sharing Agreements (OBRSAs) and sustainable supply chain alignment to satisfy modern HTA and ESG requirements

4. To project the future trends of pharmaceutical business planning: By analyzing current economic and technological advancements, this study aims to forecast the near-future horizon (2030) of the industry. This era will be characterized by a fundamental transition toward "Tech-Bio" hybrid organizations, the emergence of therapeutics custom-engineered for a single, specific patient (the "N-of-1" personalized drug model), and outcome-based healthcare paradigms

Ultimately, this dissertation aims to provide a holistic, evidence-based framework demonstrating that successful pharmaceutical commercialization is a hyper-complex procedure requiring deep scientific and technological advances, experience, creativity, as well as deep regulatory foresight. To unify this analysis, the dissertation explicitly adopts Teece's Dynamic Capabilities as an overarching meta-framework. By mapping the industry's evolution through the three core pillars of dynamic capabilities: i. sensing emergent scientific and regulatory opportunities, ii. seizing them through computational capital and strategic alliances, and iii. transforming organizational architectures to navigate

lifecycle barriers, this study demonstrates how contemporary firms build and sustain competitive advantage under conditions of profound Knightian uncertainty.

Research Questions

To systematically address the aims of this dissertation and evaluate the multidimensional transitions within the sector, this study is guided by the following core research questions:

1. How do modern biopharmaceutical firms operationalize entrepreneurial alertness to identify and validate commercial opportunities under the productivity constraints of Eroom's Law?
2. In what ways does the integration of "Computational Capital" and open innovation ecosystems redefine the strategic exploitation and clinical development of innovative drug products?
3. What multi-dimensional lifecycle management strategies and value-generating agreements are utilized by firms, in order to navigate post-exclusivity market restrictions and limitations raised by the various HTA and ESG requirements?
4. In what ways will the transition toward 'Tech-Bio' hybrid organizations, personalized 'N-of-1' genetic medicines, and decentralized manufacturing ecosystems redefine the 2030 horizon for biopharmaceutical business planning and value creation?

Research Methodology and Design

In alignment with the requirements for advanced study in Innovation Management and Entrepreneurship, this dissertation employs a Case-Illustrated Conceptual Synthesis (or an Integrative Literature Review operationalized through a Multi-Case Sectoral Analysis). Rather than focusing on a single, isolated organizational case study, this methodology is designed to synthesize diverse and disconnected data streams, specifically referring to the pharmacoeconomics sector, dynamic capabilities, and digital transformation, in order to build a new, unified conceptual model for the pharmaceutical industry. To demonstrate analytical rigor, these synthesized theoretical streams are supported by specific key industry

leaders, such as Novartis, Pfizer, Merck, and Novo Nordisk, which function as real-world case illustrations to validate the conceptual framework. This blended approach allows the research to map macro-level innovation and commercialization trends across the pharmaceutical lifecycle while using industry case-studies to demonstrate the practical application of theories such as Teece's Dynamic Capabilities. By synthesizing these diverse cases through this unified analytical meta-framework, the study establishes a comprehensive understanding of how innovative business planning and opportunity exploitation are redefining value creation and value proposition in the global healthcare ecosystem.

1. Chapter 1: Opportunity Identification and Conceptual Planning

This chapter explores the foundational mechanisms through which "innovative drug products" are first recognized, conceptualized, and engineered as viable commercial opportunities within the modern biopharmaceutical landscape.

1.1 The Epistemology of Opportunity: From Discovery to Systematic Creation

To establish a rigorous conceptual framework for biopharmaceutical business planning, one must first deconstruct the ontological nature of a commercial "opportunity." Historically, the terminology was applicable in the pharmaceutical industry under the wider perspective Kirznerian model of *Discovery Theory* (Kirzner, 1997). According to this model, the opportunities were represented as objective phenomena generated by exogenous commercial and financial phenomena, or remote scientific discoveries (e.g., the accidental discovery of penicillin). Thus, according to this traditional approach, the role of research and development (R&D) was isolated to scientific discoveries, as to "search" for and "find" novel chemical compounds for therapeutic purposes.

However, according to the modern biopharmaceutical innovation approaches, a fundamental transition towards the principles of Creation Theory is required, as the entrepreneurial opportunities are not discovered, but rather created endogenously through iterative actions, social construction, and experimentation (Alvarez & Barney, 2007).

Unlike discovery theory, this perspective assumes high uncertainty and that opportunities emerge from an entrepreneur's actions and market feedback.

Specifically in the pharmaceutical sector, which is characterized by high complexity, intense competitiveness and strict regulations, the commercial future cannot be reliably predicted via probabilistic risk models; instead, strategic planners operate under true Knightian uncertainty (Knight, 1921), where the possible outcomes of the endeavor are entirely unknown and unmeasurable (distinct from risk, which is quantifiable via probability). Subsequently, pharmaceutical entrepreneurship is characterized by sequences of unique, non-repetitive events of ambiguity» and unmeasurable uncertainty (Knight, 1921).

Based also on the fundaments and the theoretical framework proposed by Ardichvili, Cardozo, and Ray (2003), opportunity identification in pharmaceutical sector should not be conceived as a discrete, occasional event, but rather as a multi-stage, cyclical and repetitive progression, fundamentally shaped by social and organizational capabilities.

When applied to the highly complex and competitive biopharmaceutical sector, this implies that a viable commercial opportunity is rarely a static, pre-existing entity awaiting empirical discovery. Consequently, the synthesis of a novel molecular structure is not *a priori* synonymous with a market opportunity; and should be initially considered as merely a foundational scientific prerequisite.

In compliance also with the principles of constructivist epistemology (where knowledge is not discovered, but actively constructed by human beings based on their experiences, social interactions, and mental constructs), contemporary pharmaceutical firms are requested to cultivate the opportunity through a continuous, iterative cycle of strategic action, environmental feedback, and structural readjustment (Gartner, 1985; Weick, 1979).

1.1.1 Entrepreneurial Alertness as a Dynamic Capability

In contemporary entrepreneurial opportunity identification process, the "Entrepreneurial Alertness" plays a fundamental role. The principle was originally proposed by Kirzner (1973) as an individual entrepreneur's cognitive ability to identify any potential market disequilibrium that could lead to strategic management advances. Tang, Kacmar, and Busenitz (2012) have re-defined entrepreneurial alertness as a construct comprising three distinct, sequential dimensions: i. scanning and searching for new information, ii. associating and connecting previously irrelevant information, and iii. evaluating and concluding whether these connections represent a viable commercial architecture.

In the context of a highly complex biopharmaceutical firm, this cognitive triad functions as a critical, macro-level "Dynamic Capability"—specifically, the organizational capacity to continuously "sense" emergent scientific, regulatory, and commercial opportunities under conditions of extreme uncertainty (Teece, 2007). This systemic capability is dependent on the «absorptive capacity" of the entity (Cohen & Levinthal, 1990), which is expressed as the ability to recognize the significance of external scientific breakthroughs, and accordingly

to adopt and integrate them into the internal entrepreneurial procedures. Hence, a successful pharmaceutical business planning is not merely assigned to find a promising therapeutic compound, but also to enhance the organizational alertness and to actively assess the clinical and economic parameters that transform a chemical compound into an exploitable asset.

1.1.2 The Multi-Dimensional Operationalization of Alertness

The operationalization of these three dimensions could be further comprehended through the specific industry case studies below:

i. The Scanning Dimension (Academic Integration): The Case of Novartis.

A major factor of significance for opportunity identification and alertness corresponds to a high interaction and high collaboration relationships with Academic institutions. By this approach, any high-value information emerges, is immediately scanned at a first stage by the external academic ecosystems, where increasingly reliant and deep integration relationships, have been established. Such paradigms could be found in the case of Novartis pharmaceutical industry, where high organizational alertness was demonstrated through early identification and commercialization activities in the case of Chimeric Antigen Receptor T-cell (CAR-T) therapy. By actively participating and evaluating early-stage clinical data generated at the University of Pennsylvania, it was recognized by Novartis strategic planners that *ex vivo* cellular engineering represented a significant opportunity in oncology. This resulted into the establishment of a premier industry-academia alliance, leading to the final approval of tisagenlecleucel (Kymriah) therapy. This required the alertness to be focused not only to the underlying science and the therapeutic mechanisms, but also to recognize that the process required a completely novel, decentralized manufacturing supply chain and an outcome-based pricing model (Hwang et al., 2017).

ii. The Scanning Dimension (Digital Data Ecosystems): The Case of Roche and Flatiron Health

Apart from the aforementioned scanning for potential biological compounds, the contemporary entrepreneurial alertness refers also to the continuous scanning for emerging data ecosystems. A representative example of this trend is Roche pharmaceutical company's approach. In this case the pharmaceutical company recognized that the future of oncology commercialization should not only be attributed to molecular biology techniques, but also to the accumulation of Real-World Data (RWD). After scanning and evaluating digital health data generated within thousands of community oncology clinics, Roche finally recognized a pattern of highly fragmented and unstructured patient information, indicating a massive unexploited asset for future exploitation.

Subsequently, Roche proceeded in 2018 into the acquirement of Flatiron Health, a healthtech company dedicated to assessing and helping cancer centres deliver better care for patients. Through clinical and data science, the company was specialized into translating patient experiences into real-world evidence (RWE) to improve treatment, inform policy, and advance research.

By this move, Roche executed a strategic market entry, as they acquired the "absorptive capacity" to continuously scan real-world longitudinal patient outcomes. This organizational alertness allowed Roche to effectively accelerate label expansions for therapeutics like the anticancer medication Alecensa (alectinib) where the need for traditional, costly and elongated Phase III comparative trials in specific therapeutic indications, were bypassed (Miksad & Abernethy, 2018).

The strategic approach and necessity of scanning digital health ecosystems was further enhanced by its ability to solve cases lying in the "N-of-small" statistical paradox (the mathematical reality that smaller sample sizes produce wildly more variable) in rare disease indications. A representative example could be found in the case of Pfizer's commercial lifecycle management and the dynamic capability demonstrated in Ibrance (palbociclib) pharmaceutical product. Although the substance was originally approved by the Authorities for hormone receptor-positive (HR+) metastatic breast cancer in female patients, Pfizer recognized a latent clinical need within the male breast cancer demographic. However, since male breast cancer is an ultra-rare oncology subset, the execution of a traditional, statistically-powered Phase III randomized controlled trial, proved to be mathematically and logistically impossible within a commercially viable timeframe.

Thus, instead of abandoning the male patients indication, Pfizer's strategic planners utilized their organizational alertness to scan external, highly curated digital data ecosystems. By deeply analyzing real-world patient data sourced from the Flatiron Health database and IQVIA (an other major global healthcare technology and clinical research company) insurance claims network, Pfizer was able to systematically extract electronic health records (EHRs) of male patients who had been treated off-label with palbociclib (Wedam et al., 2020). By structuring this fragmented real-world data into regulatory-grade Real-World Evidence (RWE), Pfizer successfully demonstrated the required safety and efficacy of the administration. Finally, in 2019, the FDA (United States Food and Drug Administration) approved a (historic) label expansion for Ibrance to include also male patients, based entirely on the aforementioned RWE data, succeeding to bypass a physical clinical trial (Wedam et al., 2020).

iii. The Scanning Dimension (Synthetic Control Arms): The Case of Amgen and Blincyto

Furthermore, the alertness to digital data ecosystems is increasingly utilized to construct Synthetic Control Arms (SCAs).

In classical clinical trial methodology, the Randomized Controlled Trial (RCT) represents the standard clinical approach, relying on prospective randomization to equally distributed known and unknown variables between the experimental and control population. However, in ultra-rare diseases or highly fatal oncology, prospective randomization is frequently hindered by two difficulties: i. the mathematical impossibility of recruiting a statistically powered sample size, especially in the case of rare fatal diseases and ii. the ethical issues raised subjecting terminal patients to a placebo or a highly toxic substance as well ineffective treatments.

For this purpose, pharmaceutical planners have proceeded into utilization of SCAs (formally known in regulatory literature as "externally controlled trials") mostly characterized by retrospective statistical assessment. By utilizing Real-World Data (RWD) which were previously acquired from Electronic Health Records (EHRs), global disease registries, and performed clinical trials, researchers algorithmically synthesize a comparator population

that mirrors the exact baseline characteristics of the experimental single-arm group (Thorlund et al., 2020).

This advanced capability was demonstrated by Amgen pharmaceutical company during the regulatory submission for Blincyto (blinatumomab), a highly innovative bispecific T-cell engager (BiTE) developed for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Due to the highly aggressive and fatal nature of this specific leukemia variant, the submission of patients to a physical "control arm" and subsequently to highly toxic and ineffective ineffective chemotherapy treatments raised serious ethical concerns and difficulties n the recruitment process. For this purpose, Amgen scientists proceeded into the evaluation of historical clinical trial databases and patient registries across multiple international study groups, in order to construct a highly weighted, propensity-score-matched external control arm (Gökbuget et al., 2016). By performing a digital simulation of the control group using historical Real-World Data, Amgen planners could extrapolate the pharmaceutical performance in their single-arm Phase II trial. This approach was accepted by various Authorities (FDA and EMA; European Medicines Agency), granting accelerated approval (Gökbuget et al., 2016). This strategic decision highlights that modern opportunity exploitation relies heavily on the *in silico* assessment to engineer digital comparators, leading to an accelerated access to global market.

iv. The Scanning Dimension (Computational Capabilities): The Case of AstraZeneca and BenevolentAI

The scanning dimension also applies to the identification of computational capabilities that can fundamentally challenge the principles of the Eroom's Law (described in paragraph 1.2.1 below). In cases of highly complex, multifactorial diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD) the pharmaceutical company AstraZeneca had early recognized the epistemological limits of traditional, human-driven approaches mostly based on basic research performed in Universities and Institutions. Thus, AstraZeneca's strategic planners had identified the critical role of an emerging Artificial Intelligence (AI) sector, and for this purpose forged a strategic alliance with BenevolentAI

company. This firm had already developed critical technologies capable of combining and connecting millions of disparate peer-reviewed papers, clinical trial results, and genomic databases. Through this alertness, AstraZeneca was able to identify potential biological pathways that were until then unexploited from traditional researchers. This alliance led to the identification of multiple novel, AI-generated targets that were subsequently validated *in vitro* and advanced into AstraZeneca's portfolio (Paul et al., 2021).

v. The Associative Dimension (Repurposing): The Case of Celgene.

As previously been explained, the associative dimension of alertness is expressed as the ability to connect seemingly unrelated biological phenomena under a new theurapeutic perspective. This approach could also include the utilization of older often unsuccessful medical products.

A typical example is the case of the previously banned thalidomide compound. Initially introduced during the 1960s, it was accused on causing teratogenesis (severe, specific birth defects) when taken during the critical first trimester of pregnancy. However, researchers exhibited profound entrepreneurial alertness by systematically connecting disparate immunological data to the molecule's underlying anti-angiogenic (blood-vessel starving) properties (D'Amato et al., 1994). The opportunity was cognitively created by Celgene's strategic planners, who associated an abandoned chemical compound with the emergent pathophysiological understanding of multiple myeloma, ultimately transforming it into a successful therapeutic product Revimid. (Dredge et al, 2002).

vi. The Associative Dimension (Clinical Anomaly to Latent Market): The Case of Pfizer and Sildenafil

The associative dimension of alertness could also be demonstrated when strategic planners deliberately reframe a clinical "failure" or unexpected physiological anomaly as a solution to a previously unaddressed market deficit. A typical example for this approach is the development of Sildenafil (Viagra) by Pfizer Pharmaceutical company. Originally synthesized as a phosphodiesterase type 5 (PDE5) inhibitor to treat cardiovascular

conditions such as angina pectoris and hypertension, the molecule failed to meet its primary efficacy targets in early clinical trials (Ghofrani, Osterloh, & Grimminger, 2006).

However, Pfizer's clinical and strategic teams exhibited profound associative alertness. Rather than dismissing the reported "adverse effect" of pelvic vasocongestion and unexpected erections in male participants, planners associated this physiological mechanism with a massive, latent, and heavily stigmatized commercial market: erectile dysfunction (ED). By pivoting the clinical process towards the exploitation of this specific side effect, Pfizer did not invent a new molecule; they introduced a novel, multi-billion-dollar therapeutic category by associating an existing chemical compound with a newly defined patient population (Berger, 1998).

vii. The Associative Dimension (Cross-Therapeutic Pathway Sensing): The Case of Biogen and Dimethyl Fumarate

Apart from the exploitation of any potential aforementioned adverse events (i.e. the unexpected medical occurrence that happens to a patient during medical treatment or a clinical trial) explained above , the organizational alertness could also include cases of "cross-therapeutic" pathways, where a drug's fundamental mechanism of action is switched to an entirely different disease state. For example, Biogen Pharmaceutical company demonstrated organizational alertness through the commercialization of Dimethyl Fumarate (Tecfidera). Originally utilized as an industrial chemical compound, the molecule was initially formulated as a localized treatment for severe psoriasis in Germany (Fumaderm) and possessed limited global commercial value in dermatology (Linker, R. A., & Gold, R. , 2013; Mrowietz, et al, 2007).

However, Biogen's R&D planners recognized the active ingredient core mode of action: the activation of the Nrf2 signaling pathway, which fundamentally protects cells from oxidative stress and exerts profound immunomodulatory effects (Linker & Gold, 2013). Biogen's alertness is identified through the successful association of this anti-inflammatory mechanism with the complex neurodegenerative pathology of Multiple Sclerosis (MS). By aligning a dermatological asset with a central nervous system deficit, they successfully repurposed and patented the molecule as an oral MS treatment, creating a successful

pharmaceutical product that fundamentally altered the Standard of Care (SoC) for neuro-immunological patients.

viii. The Associative Dimension (Dose-Dependent Expansion): The Case of Novo Nordisk and Semaglutide

The associative alertness demonstrated in the contemporary pharmaceutical industry landscape by Novo Nordisk dictates how innovative firms navigate the boundaries within a therapeutic environment. Originally developed, dosed, and approved by regulatory authorities strictly for glycemic control in Type 2 Diabetes Mellitus (T2DM), the GLP-1 receptor agonist semaglutide was initially commercialized under the brand Ozempic. However, clinical observations consistently highlighted a secondary dose-dependent effect: delayed gastric emptying and enhanced central satiety, leading to significant reductions in energy intake and body weight (Blundell et al., 2017; Wilding et al., 2021). The company's strategic planners associated this specific pharmacological secondary effect with a viable commercial solution to the global, predominantly untreated obesity epidemic. Instead of accepting the observed weight loss merely as a 'favorable side effect' on a diabetes label, they actively identified a distinct commercial opportunity and systematically engineered a parallel asset. By re-engineering the dosage and executing massive, bespoke cardiovascular outcomes trials to secure a separate regulatory and reimbursement pathway (Lincoff et al., 2023), they successfully launched Wegovy. This associative alertness effectively transformed a specialized endocrinology product into the foundational architecture of the modern global obesity market (Müller et al., 2022).

ix. The Evaluative Dimension (Tissue-Agnostic Regulatory Engineering): The Case of Loxo Oncology

The evaluative dimension of entrepreneurial alertness is profoundly illustrated by companies capable of recognizing and exploiting imminent epistemological shifts within regulatory bodies. Historically, agencies such as the FDA and EMA classified and regulated oncology therapeutic compounds strictly by assigning on anatomical origin (e.g., pulmonary, hepatic, or mammary carcinomas). This currently obsolete approach necessitated separate, long-lasting and highly capitalized Phase III clinical trials for every

individual organ system subjected to therapy. However, Loxo Oncology, by demonstrating exceptional evaluative alertness, recognized an emerging regulatory tendency to abandon this anatomical framework in favor of contemporary approaches including genomic-defined precision medicine.

In detail, the pharmaceutical company has developed the active substance Larotrectinib (brand name Vitrakvi) a highly selective, ATP-competitive inhibitor of the tropomyosin receptor kinases (TRK), specifically the TRKA, TRKB, and TRKC kinases. encoded by the *NTRK1*, *NTRK2*, and *NTRK3* genes, respectively. It was found that when a gene fusion occurs between the aforementioned genes and a partner gene, chimeric TRK proteins are produced that remain permanently activated, allowing the proliferation and survival of cancer cells.

Instead of executing a traditional, organ-specific clinical trials for the active substance, the company's strategic planners evaluated the regulatory viability of "basket trials." These innovative clinical protocols were executed by dividing group patients exclusively based on the presence of NTRK gene fusion as a common molecular biomarker (Woodcock & LaVange, 2017). Because NTRK fusions are extremely rare, present in less than 1% of common solid tumors, executing traditional Phase III clinical trials was mathematically and logistically impossible. By actively collaborating with regulators and communicating this novel biosynthetic approach, Loxo successfully achieved a historic "tissue-agnostic" accelerated approval based on a consolidated dataset of patients with various cancer types harboring the mutation (Drilon et al., 2018; Pestana et al., 2020). This evaluative judgment completely redefined the commercial architecture site-specific pharmaceutical products, in cases that the conventional evaluation is considered mathematically and logistically impossible.

x. The Evaluative Dimension (financial market incentives): The Case of Spark Therapeutics

Apart from the field of clinical trials design discussed in the previous cases, the evaluative dimension also includes the strategic exploitation of various financial incentives explained above and designed by regulators to stimulate high-risk R&D activities. In a relevant case, Spark Therapeutics took advantage of this financial capability during the commercialization

of Luxturna (voretigene neparvovec), the first FDA-approved *in vivo* gene therapy for an inherited retinal disease (Russell et al., 2017).

In detail, Spark's business planners evaluated the commercial landscape and recognized that the ultra-rare patient population (a few thousand globally) posed an extreme barrier to recover research and development costs under traditional pharmacoeconomic models. To construct a viable commercial architecture, they resorted to applying for the FDA's Priority Review Voucher (PRV) program, specifically designed for rare pediatric diseases (Hwang et al., 2019).

Upon Luxturna's approval, Spark was awarded of a PRV approval, which was then subsequently sold to Jazz Pharmaceuticals for $110 million (Hampson et al., 2018). This demonstrates that modern entrepreneurial alertness involves evaluating regulatory legislation not just for compliance, but also as mechanisms to introduce innovative pharmaceutical products in global market.

Table 1.1.: The Multi-Dimensional Operationalization of Entrepreneurial Alertness

Dimension of Alertness	**Strategic Focus**	**Pharmaceutical Case**	**Entrepreneurial Action & Commercial Enactment**
1. Scanning & Searching	Academic Integration	Novartis *(Kymriah)*	Scanned early-stage academic data (UPenn) to identify the CAR-T paradigm shift. Enacted the market by engineering novel decentralized supply chains and outcome-based pricing models
	Digital Data Ecosystems	Roche *(Flatiron Health)*	Scanned the digital landscape to acquire Real-World Data (RWD) capabilities. Utilized Real-World Evidence (RWE) to bypass protracted Phase III comparative trials.
	Digital Data Ecosystems	Pfizer	Scanned external RWD/EHR databases (Flatiron, IQVIA) to

	(Label Expansion)	*(Ibrance)*	extract electronic health records of male patients treated off-label. Synthesized RWE to successfully secure a label expansion for an ultra-rare demographic without a physical trial.
	Synthetic Control Arms	Amgen *(Blincyto)*	Scanned historical clinical trial databases to construct a highly weighted, propensity-score-matched external synthetic control arm. Digitally simulated the control group to bypass the ethical and mathematical barriers of traditional randomization.
	Computational Capabilities	AstraZeneca *(BenevolentAI)*	Scanned the AI sector for advanced "knowledge graph" technology. Sensed unexploited biological pathways to identify AI-generated targets for complex diseases (e.g., CKD, IPF).
2. Associating & Connecting	Asset Repurposing	Celgene *(Revlimid)*	Associated disparate immunological data with the anti-angiogenic properties of an abandoned teratogen (thalidomide). Redefined the mechanism of action to create a multiple myeloma blockbuster.
	Clinical Anomaly to Latent Market	Pfizer *(Sildenafil)*	Cognitively reframed a failed cardiovascular endpoint and associated a reported adverse event (vasocongestion) with a massive,

			unaddressed latent market (erectile dysfunction).
	Cross-Therapeutic Pathway Sensing	Biogen *(Tecfidera)*	Associated the fundamental Nrf2 signaling mechanism of a localized psoriasis treatment with the complex neurodegenerative pathology of Multiple Sclerosis.
	Dose-Dependent Expansion	Novo Nordisk *(Semaglutide)*	Associated a secondary dose-dependent physiological effect (delayed gastric emptying) of a diabetes drug with the global, predominantly untreated obesity epidemic.
3. Evaluating & Judging	Tissue-Agnostic Regulatory Engineering	Loxo Oncology *(Vitrakvi)*	Evaluated an epistemological shift in FDA trial designs. Leveraged genetic "basket trials" to secure a tissue-agnostic approval, completely bypassing traditional anatomical trial requirements.
	Statutory Financial Incentives	Spark Therapeutics *(Luxturna)*	Evaluated regulatory statutes to offset the high R&D costs of an ultra-rare gene therapy. Aggressively pursued and monetized an FDA Priority Review Voucher (PRV) as a secondary liquid asset ($110M).

1.1.3 Modern Systematic Sensing and Regulatory Intelligence

Within the highly competitive contemporary biopharmaceutical landscape, the entrepreneurial alertness of innovative firms must also be operationalized at an industrial scale. Modern pharmaceutical enterprises no longer rely on a stochastic discovery paradigm (characterized by probabilistic, trial-and-error methodologies) but rather on deterministic, logically engineered design. To achieve this, contemporary firms extensively utilize advanced data architectures and predictive pharmacological modeling to systematically scale their organizational alertness. A representative case of this industrialized sensing is the rapid repurposing and commercialization of Remdesivir by Gilead Sciences.

Originally synthesized and evaluated as a therapeutic candidate for the Ebola and Marburg viruses, its mode of action was swiftly redirected against the emergent SARS-CoV-2 threat. This strategic pivot was executed by meticulously evaluating the compound's antiviral activity *in silico*, leveraging continuous computational assessments of a broad-spectrum nucleotide prodrug library against emergent viral phylogenies (Eastman et al., 2020). This case demonstrates that modern opportunity identification requires organizational foresight and prediction mechanisms to cultivate potential pharmacological reserves and computational screening capabilities long before a distinct commercial market need actually emerges (Pushpakom et al., 2019).

Furthermore, contemporary entrepreneurial alertness extends significantly beyond biological and chemical innovation into the highly specialized domain of "Regulatory Intelligence." Opportunity identification is now intrinsically linked to the successful recognition of regulatory gaps and the strategic utilization of expedited registration pathways established by global health authorities. By aggressively exploiting frameworks such as the FDA's Breakthrough Therapy Designation (BTD) and the EMA's Priority Medicines (PRIME) scheme, the pharmaceutical firms not only accelerate the administrative review timeline, but they fundamentally alter the evidentiary burden. These designations provide critical flexibilities during the submission process, including the acceptance of surrogate clinical endpoints, rolling data submissions, and early, iterative

dialogue with regulators, which drastically mitigate the risk of late-stage Phase III clinical attrition (Darrow, Avorn, & Kesselheim, 2014; Bujar et al., 2019).

As the pharmaceutical industry gradually transitions toward an infrastructure reliant on computational capital, regulatory intelligence must also pivot to include the novel paradigms of digital therapeutics and AI-driven clinical protocols. Strategic planners are increasingly required to demonstrate increased levels of entrepreneurial alertness towards emergent legal frameworks, as the EU Artificial Intelligence (AI) Act, which strictly governs the deployment of algorithmic systems in healthcare (Vokinger & Gasser, 2021). To safely and effectively exploit advanced "Agentic AI" systems during the earliest stages of conceptual planning, firms must proactively evalaute these regulatory boundaries in order to ensure compliance without restricting the overall innovation process (Mökander et al., 2022). Ultimately, under contemporary market conditions, a pharmaceutical business plan is considered fundamentally unviable if its scientific novelty is not combined with a meticulously examined regulatory and digital compliance pathway.

1.2 The Innovation-Cost Paradox and the "Orphan Blockbuster" Strategy

In order to comprehend the evolution of opportunity identification within the contemporary biopharmaceutical landscape, it is necessary to analyze the recent structural and epistemological decline of the traditional pharmaceutical business model. Throughout the latter half of the 20th century, the pharmaceutical industry value proposition architecture was vastly characterized by a mass-market "blockbuster" drug delivery approach. This model relied heavily on the development and commercialization of high-volume, primary care therapeutic formulations designed to address prevalent, symptomatic conditions across broad patient populations. However, as extensively documented in the pharmacoeconomic literature (Munos, 2009; Kaitin, 2010), has gradually declined under the effect of an innovation-cost paradox. Following the exhaustion of easily tractable biological targets and pharmaceutical modes of action —a phenomenon frequently characterized as the depletion of the industry's "low-hanging fruit" (Pammolli, Magazzini, & Riccaboni, 2011; Scannell et al., 2012)—the scientific complexity in drug discovery and providing innovative

pharmaceutical products, was intensified exponentially. Consequently, the capitalized research and development (R&D) expenditures required to introduce a novel mass-market chemical compound through the typical clinical and regulatory pathways have also been exponentially increased, while in parallel the corresponding probability of technical and regulatory success (PTRS) has exponentially declined (Wouters et al., 2020). This unsustainable financial trajectory led to a fundamental strategic realignment toward highly targeted, genetically defined therapeutic compounds.

1.2.1 The Pharmacoeconomics of Eroom's Law and R&D Attrition

This phenomenon is best attributed as "Eroom's Law" (Scannell et al., 2012), which describes the exponential decline in R&D output efficiency. The authors observed that the number of New Molecular Entities (NMEs) approved per billion US dollars of R&D expenditure had halved approximately every nine years since 1950. The financial impact of this decline was quantified by DiMasi, Grabowski, and Hansen (2016), who determined that the total capitalized, pre-approval cost of bringing a single novel molecule to market has increased to a then value of approximately $2.6 billion. This inverse application of Moore's Law (the empirical observation and business projection that was introduced in 1965 by G. Moore and referring to semiconductor and computing industry, where it was predicted a duplication of semiconductor performance every two years), is characterized by four fundamental drawbacks.

1. *The Escalating Standard of Care and the progressively rising baseline of therapeutic efficacy:*

Currently, for the successful introduction of a novel pharmaceutical compound, a statistically significant clinical superiority against established, low-cost generics must be proven, including extended Phase III trials. Because the already established "Standard of Care" (SoC) has proved to treat the condition effectively and also been certified by Authorities and Institutions, during the introduction of a novel pharmaceutical compound the observable "effect size" (Δ; expressed as the incremental clinical benefit provided by the novel molecule over the already approved pharmaceutical product), is drastically compressed. According to fundamental biostatistical principles for analysis, the required

sample size (N) needed to achieve statistical significance ($p < 0.05$) is inversely proportional to the square of the effect size ($N \propto 1/D^2$). Thus, since on the one hand the incremental benefit of a new drug substance becomes marginally smaller, on the other hand the required patient size requested for an adequate performance of a clinical study increases exponentially, which further require additional studies and resources (multi-center Phase III clinical trials) including an additional involvement of thousands of new participants (Fogel, 2018).

Furthermore, it is considered a common practice within the pharmaceutical industry the cases that that if a novel pharmaceutical substance cannot mathematically demonstrate clinical superiority over previous well-established compounds, the companies are often directed to execute additional complex "non-inferiority" trials. In this case, the studies to be performed are intended to demonstrate that the new drug is not statistically less effective than the currently registered in the market pharmaceutical product while at the same time attempting to justify a superior safety, quality and efficacy profile (D'Agostino et al., 2003).

Summarizing the above, it is concluded that in either case where the superiority or the non-inferiority is pursued, and in accordance with the requirements described from various Health Authorities worldwide, a significant increase of volunteer patients (even at exponential values), and subsequently long-duration and high complexity clinical studies are requested, followed by a vast financial impact.

2. *The "Epistemological Shift" to Target-Based Reverse Pharmacology:*

Historically, the pharmaceutical discovery process throughout the 20th century operated under a classical "forward" pharmacology paradigm, heavily reliant on phenotypic screening (Swinney & Anthony, 2011). Under this framework, researchers administered extensive libraries of chemical compounds to living cells, isolated tissues, or whole organisms to observe the resultant physiological effects (the "phenotype"). This was frequently executed without a definitive understanding of the underlying molecular mechanism of action; if a compound consistently demonstrated in vivo safety and phenotypic efficacy, it was advanced through clinical development and regulatory approval.

However, catalyzed by monumental advances in molecular biology—most notably the sequencing of the human genome—and the advent of high-throughput combinatorial

chemistry and in silico molecular docking, the industry underwent a fundamental epistemological shift. Strategic focus pivoted toward a Target-Based Drug Discovery (TBDD) model, also known as "reverse" pharmacology. In this paradigm, researchers first identify and validate a specific molecular target (e.g., a genetic mutation, a kinase, or a receptor) and subsequently engineer a highly specific molecular entity explicitly designed to modulate that singular node (Swinney & Anthony, 2011).

While theoretically plausible and rational, this approach has underestimated the highly interactive, non-linear complexity of human systems biology. The TBDD paradigm operates on a simplistic assumption: that modulating a singular biological target will successfully treat a systemic disease. In reality, human pathophysiological networks are characterized by profound redundancy, robust compensatory feedback loops, and pleiotropy—wherein a single gene or pathway influences multiple distinct phenotypic traits (Barabási, Gulbahce, & Loscalzo, 2011).

Consequently, although a novel molecule may exhibit exact target binding affinity at subcellular level and target engagement *in vitro*, it often failed to demonstrate clinical efficacy *in vivo*. Even when a pharmaceutical compound successfully inhibits a specific biosynthetic pathway, the human biological system frequently bypasses the pharmacological blockade by upregulating alternative biological mechanisms. As these compensatory biological mechanisms typically do not become clinically observable until the drug is tested in large, diverse human cohorts, clinical failures are disproportionately concentrated in late-stage Phase II (proof-of-concept) and Phase III trials (Waring et al., 2015). The severe financial impact of discovering a fundamental biological flaw only after proceeding into significant expenditures at late-stage clinical development, is a core structural component of the aforementioned Eroom's Law productivity crisis.

In order to comprehend the financial and clinical gravity of this epistemological shift, it is significant to examine specific therapeutic areas where simplistic TBDD approaches resulted in historic late-stage failures:

- *The Amyloid-Beta Hypothesis in Alzheimer's Disease:* One of the historically most characteristic cases of a target-based failure on diseases treatment could be found in the attempts on Alzheimer's disease-modifying therapies. After decades of extensive search activities following the identification of amyloid-beta plaques in

the brains of Alzheimer's patients, various highly specific molecules were developed by the pharmaceutical industry (such as BACE inhibitors and early monoclonal antibodies), that were engineered in order to interrupt amyloid production or eliminate existing plaques formation. Although the administration of these drugs succeeded to interact with their target, leading to an effective inhibition of amyloids formation in Phase II and Phase III trials, they repeatedly failed to sustain or reverse the cognitive decline of the patient that applied (Panza et al., 2019). From the above, it was concluded that the pharmaceutical industry researchers were misled to the initial assumption that amyloid was the only source of cognitive malfunction, underestimating the complex, multifactorial systems biology of human neurodegeneration. Therefore the unsuccessful introduction of Amyloid-Beta based pharmaceutical treatments in Alzheimer's disease was recorded as one of the highest and most expensive clinical failures in pharmaceutical history.

- *Compensatory Kinase Networks in Oncology:* Under the aforementioned Target-Based Drug Discovery (TBDD) model applied in targeted oncology, various highly specific tyrosine kinase inhibitors (TKIs) have been synthesized for potential use in targeted oncology. Although the application of these molecules proved initially to case While these targeted therapies often produce rapid initial tumor deterioration (by inhibiting specific mutant kinases as BRAF or EGFR), the clinical efficacy proved to be often temporary. Due to the biological complexity of the tumor microenvironment, the cancer cells can bypass the process by utilizing alternative kinase signaling pathways, leading to a rapidly acquired clinical resistance (Lovly & Shaw, 2014).

3. *Expanding Regulatory Stringency and the "Cautious Regulator" Problem:* Over the past several decades, global regulatory authorities (such as the FDA and EMA) have proceeded into a significant structural decrease in pharmaceutical risk tolerance, causing subsequently fundamental changes in of drug product development process and thus to the overall pharmacoeconomic environment. Due to various by highly publicized post-market safety withdrawals of pharmaceutical products, took place in the late 20th and early 21st centuries, the regulatory approach was shifted towards a conservative approach regarding drug-induced adverse events (Scannell et al., 2012).

In order also to identify rare idiosyncratic and low-frequency toxicities prior to final pharmaceutical product, regulatory Authorities now routinely request to submit vast in number, costly and elongated Phase III clinical trials, also mentioned previously. Consequently, this logistic and operational complexity usually result to a significant extension of the average Time-to-Market (TTM) period and the final launch of the pharmaceutical product to the global market. However from a corporate finance perspective, any unpredicted delay could pose a significant financial impact, as pharmaceutical business planning relies heavily on Discounted Cash Flow (DCF) valuation models, where any extension of the TTM period heavily affects the value of future commercial revenues. This combination of increased costs due to additional studies required, and the delayed market entry could reduce drastically the pharmaceutical project's Net Present Value (NPV) and Internal Rate of Return (IRR), where cases where scientifically viable molecules became commercially unjustifiable, have been observed (DiMasi, Grabowski, & Hansen, 2016; Schuhmacher, Gassmann, & Hinder, 2016).

4. *Diseconomies of Scale and the Organizational "Sunk Cost" Trap:*

During also the late 20th and early 21st centuries, the pharmaceutical industry attempted to counterbalance the observed at that period declining productivity through massive corporate consolidation and extended merging process between companies, motivated by the assumption that the consistently increased R&D budgets would be mediated through merged economies of scale. However, relevant management literature have demonstrated that this hyper-expansion paradoxically posed serious disadvantages in the attempted scale of the endeavor (Garnier, 2008). In detail, as the R&D activities overexpanded, this activity was also characterized by hyper-bureaucratic procedures and departments or teams operating often in isolation, rarely sharing information, resources, or goals with other merged departments. This has resulted into information asymmetry and fragmented decision-making between early-stage discovery scientists and late-stage clinical developers before the pharmaceutical product launch. Within this rigid corporate architecture, strategic planners and portfolio committees frequently subjected to the "sunk cost fallacy" (Arkes & Blumer ; 1985) and the behavioral escalation of commitment. As corporate incentives are often structurally aligned towards achieving short-term milestones instead of focusing on the long-term entrepreneurial development and viability, a hesitation to terminate ongoing

unsuccessful projects where substantial capital had been invested, is observed. Consequently, large pharmaceutical enterprises often demonstrated a catastrophic heuristic operational inability (a problem-solving approach to produce a satisfactory solution quickly and efficiently when conventional methods are too slow; Paul et al., 2010). Thus, instead of terminating potential therapeutic substances during the early stages of the relatively inexpensive preclinical or Phase I trials of pharmaceutical assessment, the Pharma companies often unjustifiably proceeded into performing highly capitalized, late-stage Phase III trials, ensuring a maximum financial consequence if the asset inevitably failed due to a lack of *in vivo* efficacy. Representative examples, could be found below:

Example 1: The "Sunk Cost Trap" : The Case of Pfizer and Torcetrapib:

A typical example of the sunk cost fallacy and the escalation of commitment in modern pharmaceutical operational history, could be found in the case of Pfizer's development of torcetrapib cardiovascular pharmaceutical product. In detail, torcetrapib consists of a CETP inhibitor designed to raise HDL (the "good" cholesterol) in human organism, intended to replace the well-established in pharmaceutical market but aging statin medication Lipitor. During early Phase II trials, clinical data indicated an alarming side-effect: torcetrapib application was identified to cause a statistically significant increase in patients' blood pressure. Under a strict heuristic approach explained previously, this cardiovascular toxicity in a cardiovascular drug should have triggered an immediate termination of the assessment. However, due to the fact that Pfizer had already invested significant monetary amounts for the compound development and was also under a significant and consistent corporate pressure to replace Lipitor's revenue, organizational decision-makers subjected into performing the "sunk cost fallacy", as they estimated that the blood pressure increase side-effect as ultimately manageable. Subsequently, the company proceeded in 2006 into performing an extensive 15,000-patient Phase III clinical trial, that was finally halted by an independent data monitoring committee. Torcetrapib active substance not only failed to prevent heart disease incidents, but it was finally proved to significantly increase cardiovascular morbidity and mortality rates. Pfizer finally was obligated to terminate the asset after incurring substantial financial losses, estimated at approximately $800 million on the pharmaceutical product development (Tall et al., 2015).

Example 2: "Diseconomies of Scale": The GSK Mega-Merger and the CEDD Reorganization:

A representative illustration of the concept of diseconomies of scale could be found in the case of the massive (£50 billion) merger of two British pharmaceutical giants Glaxo Wellcome and SmithKline Beecham that created GlaxoSmithKline (GSK) in 2000. The underlying corporate thesis was that combining assets from both pharmaceutical companies would result to create an R&D budget at a level estimated at $5 billion annually, achieving unprecedented economies of scale that would eventually lead to a pharmaceutical market domination.

However, under real entrepreneurial conditions, the merger proved to create an unmanageable bureaucracy. Decision-making was divided between pharmaceutical development, preclinical assessments and clinical trial management. Subsequently, R&D productivity gradually declined, following as the organizational inefficiently to evaluate and terminate failing assets.

This situation led GSK's leadership to proceed into a fundamental deconstruction of the above-described entrepreneurial structure, including the consolidated R&D department. To restore entrepreneurial alertness, GSK separated the previously unified R&D department into smaller, highly autonomous units called Centers of Excellence for Drug Discovery (CEDDs). These CEDDs operated like independent biotechnology startups within the larger corporation, under their own budgets and decision-making autonomy, specifically designed to overcome bureaucratic obstacles and restore the ability to proceed towards effective decision-making process (Garnier, 2008).

Table 1.2: Clinical and Organizational Manifestations of Eroom's Law

Structural Pathology	**Pharmaceutical Case Study**	**Scientific / Strategic Mechanism**	**Clinical & Economic Consequence**
Target-Based Attrition (Reductionist Biology)	Alzheimer's Disease *(Amyloid-Beta Hypothesis)*	Relied on a simplistic assumption that eliminating a single pathogen (amyloid plaques) would cure a systemic disease. The approach underestimated the highly complex, multifactorial systems biology of neurodegeneration.	Although the drugs successfully cleared plaques, they failed to reverse cognitive decline in late-stage trials, resulting in one of the highest and most expensive clinical attrition rates in industry history.
Target-Based Attrition (Compensatory Networks)	Targeted Oncology *(Tyrosine Kinase Inhibitors - TKIs)*	Highly specific TKIs successfully engaged their mutant kinase targets (e.g., BRAF, EGFR) to produce rapid initial tumor deterioration. However, the complex tumor microenvironment utilized redundant, alternative signaling pathways to bypass the pharmacological blockade.	The clinical efficacy proved transient, leading to rapidly acquired clinical resistance and demonstrating that targeting a single node cannot dismantle an adaptive disease network.

The Organizational "Sunk Cost" Trap	Pfizer *(Torcetrapib)*	Following concerning cardiovascular toxicity (increased blood pressure) in early Phase II trials, organizational planners succumbed to the behavioral escalation of commitment and the "sunk cost fallacy". Due to prior investments and revenue pressures, they failed to execute a "fail fast, fail cheap" strategy.	The asset was advanced into a massive Phase III trial (ILLUMINATE), which had to be halted due to increased mortality. This resulted in catastrophic late-stage financial destruction, costing Pfizer $800 million.
The Organizational "Sunk Cost" Trap	Pfizer *(Torcetrapib)*	Following concerning cardiovascular toxicity (increased blood pressure) in early Phase II trials, organizational planners succumbed to the behavioral escalation of commitment and the "sunk cost fallacy". Due to prior investments and revenue pressures, they failed to execute a "fail fast, fail cheap" strategy.	The asset was advanced into a massive Phase III trial (ILLUMINATE), which had to be halted due to increased mortality. This resulted in catastrophic late-stage financial destruction, costing Pfizer $800 million.

Bureaucratic Diseconomies of Scale	GlaxoSmithKline (GSK) *(Mega-Merger & CEDD Reorganization)*	Driven by the assumption that a massive $5 billion R&D budget would generate economies of scale, the merger instead created an unmanageable, siloed bureaucracy with fragmented decision-making and profound information asymmetry.	R&D productivity plummeted. To restore entrepreneurial alertness and rapid "go/no-go" decision-making, the CEO had to fundamentally deconstruct the R&D model into smaller, autonomous "startup-like" units (CEDDs).

Figure 1: The Errom's law trend in pharmaceutical R&D (1950 – 2020), expressed as New Molecular Entities (NMEs) per $ 1Billion on R&D investment



1.2.2 The Economics of the Orphan Drug Paradox

In response to the systemic productivity collapse previously described, pharmaceutical business planners were now obligated to perform a radical strategic adjustment towards identifying molecules with the highest possible profit that the pharmaceutical business can extract from the specific market. This transition is characterized under the term of "Orphan Drug Paradox".

In pharmacoeconomic terms, this paradox is expressed in the cases where a drastically smaller, highly specialized patient demographic population is targeted which can paradoxically yield revenue often equivalent compared to traditional mass-market drugs, while simultaneously maintaining a significantly more secure return of the invested revenues. This security is largely derived from the unique demand-side economics of rare diseases; as these are characterized as severe conditions frequently lacking any alternative therapeutic approached. Thus, these rare therapies are characterized by an objective pricing inelasticity, allowing manufacturers to sustain premium pricing models and exclusivity (Michel & Toumi, 2012).

By deliberately targeting these rare diseases, pharmaceutical firms gain access to an artificial market incentives meticulously engineered by legislative bodies, such as the US Orphan Drug Act. These regulatory frameworks provide critical financial resources designed to overcome the inherent financial risks of the extended R&D activities that will be required, including granting extended periods of market exclusivity as well as permitting significantly reduced clinical trial sizes.

Consequently, the pharmaceutical firms are protected from the aggressive generic market introduction that could cause a drastic decrease in market share and revenues. Representative paradigms of this strategy include Alexion Pharmaceuticals' commercialization of Eculizumab active substance for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Vertex Pharmaceuticals' dominance with its Cystic Fibrosis portfolio. By successfully abandoning the highly competitive primary care sector, these firms were awarded with regulatory exclusivity as a strategic swift towards precision

biology resulting into the introduction of pharmaceutical solutions for ultra-rare conditions. These remedies are characterized by high pricing elasticity, proving that targeted regulatory engineering can yield immense, monopolistic commercial value (Wellman-Labadie & Zhou, 2010).

On the other hand, the strategic exploitation of an artificial market formed by regulations, is not restricted to the United States Authorities. In the European Union, the legislative counterpart is Regulation (EC) No 141/2000 on orphan medicinal products. Enacted to counterbalance the structural market failure associated with rare diseases (defined in the EU as conditions affecting fewer than 5 in 10,000 individuals), this regulation provides a highly profitable, legally protected commercial environment (Franco, 2013).

The most potent mechanism within the EU Orphan Regulation is the granting of a 10-year period of market exclusivity upon approval. This European exclusivity period is notably longer than the 7-year period granted by the US Orphan Drug Act. During this decade, the European Medicines Agency (EMA) and member state authorities are legally barred from accepting or approving any competing marketing authorization applications for a similar medicinal product in the same therapeutic indication (Davies et al., 2012).

Furthermore, the EMA additionally provides structural R&D subsidies through the "Protocol Assistance" process (a highly specific, reduced-fee scientific advice during the trial design phase) and significant fee waivers for regulatory submissions. For the pharmaceutical business planner, this 10-year European exclusivity guarantees a prolonged, monopolistic horizon free from any generic or biosimilar price competition, allowing the companies to secure their capitalized R&D expenditures across a much smaller patient volume while also maintaining premium, inelastic drug pricing models through European Union member states.

The US Market Paradigm: Alexion Pharmaceuticals and Soliris (eculizumab)

A typical manifestation of the Orphan Drug Paradox within the United States market, could be found in the case of the commercialization of Soliris by Alexion Pharmaceuticals. Soliris refers to a monoclonal antibody treatment, originally developed as a potential therapy for Paroxysmal Nocturnal Hemoglobinuria (PNH) disease, an ultra-rare and life-threatening blood disorder affecting approximately 1 to 2 individuals per million globally. Under

traditional mass-market pharmacoeconomics, developing a highly complex monoclonal antibody for a few thousand patients would inevitably result to a negative return on investment. However, the US Orphan Drug Act (ODA) was strategically exploited by Alexion, as by securing orphan designation, the firm obtained significant R&D tax credits, waived FDA user fees, and was awarded of a guaranteed 7-year statutory period of market exclusivity.

Furthermore, as PNH disease was characterized by absence of any other alternative therapies, the drug administration was inelastic in terms of pricing policies. Alexion launched Soliris at a price exceeding $400,000 per patient per year. Shielded from generic competition by the ODA exclusivity and subsequent patent thickets, Soliris routinely generated over $3 billion in annual global revenue prior to its loss of exclusivity, definitively proving the paradox that an ultra-rare demographic can yield mass-market financial returns (Luzzatto et al., 2018).

The European Market Paradigm: Biogen and Spinraza (nusinersen)

In the European Union, the paradox is characterized by the extensive utilization of the 10-year market exclusivity granted under Regulation (EC) No 141/2000. A definitive example of this European regulatory engineering is the commercialization of Spinraza (nusinersen) by Biogen for the treatment of Spinal Muscular Atrophy (SMA), a rare genetic motor neuron disease with lethal consequences. Upon receiving EMA approval, Spinraza was granted orphan medicinal product status, activating an 10-year access exclusivity across all EU member states. In the highly fragmented European market, where Health Technology Assessment (HTA) bodies like the UK's NICE or Germany's G-BA are aggressively requesting drug price reductions in commonly available in market cardiovascular or diabetes drugs, the orphan regulatory protection forced a different negotiation approach.

As already been protected by the EMA's decade-long exclusivity and the severe, fatal nature of SMA disease, Biogen successfully negotiated initial list prices approaching €300,000 to €500,000 for the first year of treatment across various European jurisdictions (Labbé et al., 2020). By accessing the EU Orphan Regulation, the company's strategic planners ensured that the significant capitalized costs of the oligonucleotide drug development were rapidly recovered from a limited patient population, successfully securing the asset's commercial

viability in a strict, single-payer-dominated European landscape (Simoens, Cassiman, & Dooms, 2012).

The Precision Genomic Sub-typing Paradigm: Vertex Pharmaceuticals and Kalydeco

A highly sophisticated evolution of the Orphan Drug Paradox is the strategic utilization of precision genomics to artificially fragment a larger disease population into sub-populations. This approach was followed by Vertex Pharmaceuticals company and applied in the case of commercialization of Kalydeco (ivacaftor) pharmaceutical product, a drug designated for Cystic Fibrosis (CF) treatment. Although Cystic Fibrosis (CF) is considered an orphan disease in both the US and the EU markets, a broad label for all CF patients was not targeted by the company. On the contrary, Vertex strategic planners identified a highly specific genomic sub-population of patients characterized by a specific G551D mutation, identified only in 4% to 5% of the total CF patient population (Ramsey et al., 2011).

By targeting this sub-populated demographic, Vertex achieved to secure an orphan drug approval from both the FDA and the EMA Authorities, benefiting from rapid clinical trial pathways and reduced additional documentation.

In terms of revenues, the introduction of the drug in the global market succeeded yielding approximately $300,000 per year, further supported by pricing inelasticity, establishing a statutory monopoly. This paradigm demonstrates that the Orphan Drug Paradox does not only describe a potential pricing strategy, but an overall foundational business model utilizing a genomic sub-type as a subsidized entry point for broader market dominance (Gammie, Lu, & Babar, 2015).

The Oncological Indication Expansion Paradigm: Novartis and Gleevec

Another representative demonstration of the Orphan Drug Paradox generating mass-market revenues is Novartis's development of Gleevec (imatinib) active ingredient. Originally developed for the remediation of Chronic Myeloid Leukemia (CML), Gleevec secured in 2001a regulatory approval as rare orphan oncology indication under the orphan exclusivity status. Due to a highly specific mechanism of action (inhibiting the BCR-ABL tyrosine

kinase), the drug fundamentally achieved the treatment of a fatal cancer form as a manageable chronic condition.

By the successful introduction of the orphan drug in global market, two pharmacoeconomic targets have been achieved. Firstly, due to the high drug effectiveness against the specific cancer forms, a significant increase in patients; life expectancy took place, ensuring an exponentially growing, cumulative patient base. Second, Novartis's strategic planners executed a masterful "indication sequencing" strategy. Following the initial CML approval, Novartis systematically secured subsequent orphan designations for other rare conditions utilizing similar kinase pathways, such as Gastrointestinal Stromal Tumors (GIST). Thus, by filing for multiple distinct orphan indications from a single molecule submission, Gleevec succeeded increased revenues, estimated at a sales level of approximately $4.7 billion annually (Kantarjian et al., 2013).

This case clearly indicates a potential market opportunity where a molecule developed strictly within the confines of the Orphan Drug Act can surpass the revenue of traditional, primary-care pharmaceutical products through strategic indication expansion and the compounding effect of chronic administration.

Table 1.3.: Strategic Paradigms and Commercial Manifestations of the Orphan Drug Paradox

Strategic Paradigm	**Pharmaceutical Case (Company & Drug)**	**Indication / Disease Focus**	**Strategic Exploitation Mechanism**	**Commercial & Economic Outcome**
The US Market Paradigm	Alexion Pharmaceuticals (Soliris / eculizumab)	Paroxysmal Nocturnal Hemoglobinuria (PNH); an ultra-rare blood disorder affecting 1-2 per million.	Exploited the US Orphan Drug Act (ODA) to secure R&D tax credits, waived FDA fees, and a guaranteed 7-year statutory market exclusivity.	Launched at >$400,000 per patient annually due to zero pricing elasticity, generating over $3 billion in annual global revenue prior to exclusivity loss.
The European Market Paradigm	Biogen (Spinraza / nusinersen)	Spinal Muscular Atrophy (SMA); a rare, fatal genetic motor neuron disease.	Leveraged the 10-year absolute market exclusivity granted under EU Regulation (EC) No 141/2000 to bypass aggressive pricing pressures from HTA bodies (e.g., NICE, G-BA).	Negotiated initial list prices of €300,000 to €500,000 for the first year of treatment, rapidly recouping massive capitalized R&D costs from a micro-niche patient base.
Precision Genomic Sub-typing	Vertex Pharmaceuticals	Cystic Fibrosis (CF), specifically isolated to patients harboring	Artificially fragmented a larger orphan disease into a highly specific	Priced at ~$300,000 annually. This statutory

	(Kalydeco / ivacaftor)	the G551D mutation (merely 4-5% of the total CF pool).	genomic micro-niche to effortlessly secure FDA and EMA orphan designations.	monopoly served as a subsidized financial foothold to fund subsequent combination therapies (Orkambi, Trikafta) capturing the remaining 90% of the market.
Oncological Indication Expansion	Novartis (Gleevec / imatinib)	Originally Chronic Myeloid Leukemia (CML), systematically expanded to Gastrointestinal Stromal Tumors (GIST) and other rare malignancies.	Executed a masterful "indication sequencing" strategy by continuously stacking multiple distinct orphan designations onto a single targeted kinase inhibitor.	Transformed a fatal disease into a chronic condition, compounding the prevalence of the patient base and reaching peak global sales of $4.7 billion annually.

1.2.3 "Salami Slicing" and Indication Sequencing

Building upon the economic advantages of the "Orphan Drug Paradox" discussed previously, a highly sophisticated evolution in contemporary conceptual planning has emerged. This approach is formally defined in the pharmacoeconomic literature as Strategic Indication Sequencing, and is commonly referred within the pharmaceutical industry under the term "Salami Slicing" (Rome, Lee, & Kesselheim, 2021).

Unlike the traditional primary-care drug model, where the pharmaceutical companies are targeting initial regulatory approvals for the broadest possible therapeutic application, this

contemporary model is based on deliberate access across distinct customer segments. The strategic plan is based on the approach of exploitation of ultra-rare, genetically or phenotypically defined sub-indication to serve as an initial commercial and regulatory patient base (Karas et al., 2019).

This approach could be found on a repeatable basis, solidifying the pharmaceutical lifecycle management. Recent pharmacoeconomic analyses demonstrate that the expansion of indications for existing oncology drugs now routinely surpasses the number of approvals for entirely new therapeutic entities. Once a drug secures its initial market launch, subsequent indication expansions secure a significantly increase of prescribed drug volumes and a cumulative market share. Securing an initial approval targeting patients sub-populations leads to profound strategic and financial advantages.

Once this initial approval is secured, firms frequently proceed into an "indication stacking," a phenomenon where a single product is sequentially authorized for two or more distinct orphan indications, allowing multiple periods of market exclusivity to run concurrently or consecutively (Bostyn, 2022).

The utilization of this commercial approach delivers significant strategic and financial advantages. Primarily, it allows the firm to generate fast high-margin revenue under a pricing inelasticity and absolute protection environment of statutory orphan exclusivity. However, the regulatory and ethical dimensions of this practice remain highly debated.

The accumulation of market exclusivity rights through multiple, sequenced orphan drug submissions has been directly linked to unaffordable pricing structures globally and is frequently criticized as a misuse of legislative incentives designed for genuine rare diseases (Alonso Ruiz et al., 2023).

In contrast, other researchers highlight the fact that the salami-slicing approach is fundamentally based on inherent evolutionary nature of medical science and the broader shift toward precision medicine (Horgan et al., 2022). Furthermore, it is also supported that sequential submissions is a scientifically essential approach, based on constant improvements in understanding disease pathophysiology and the existence of distinct pathogenic subtypes, lacking alternative approved treatments (Horgan et al., 2022).

Regardless of the ethical debate issue, this early market access enables the pharmaceutical product manufacturer to aggregate extensive Real-World Evidence (RWE) and safety data

under a a commercial scale, significantly mitigating any inherent clinical risk of the active molecule. In this architecture, the initial orphan drug functions as a powerful financial de-risking mechanism; as the early, monopolistic revenues act as an indirect subsidization the capitalized R&D expenditures required to execute subsequent, larger-scale Phase III trials.

Through this subsidized, iterative clinical development, the firm can progressively "slice" into larger similar or adjacent disease indications or broader demographic populations throughout the product's lifecycle period, extending market exclusivity, and mathematically maximizing the molecule's cumulative Net Present Value (NPV).

1.3 Business Model Innovation and Organizational Architecture

Within the contemporary biopharmaceutical sector, the realization of a scientific breakthrough does not possess intrinsic economic determinism. Historically, business planning often suffered from a reliance on "technological determinism", under the incorrect assumption that any inherent scientific superiority of an invention would automatically lead to an organizational success and market adoption. In this case, scientific breakthroughs are not always followed by equivalent economic returns.

Even the most profound scientific discoveries can fail commercially if they are not properly positioned in the market, especially in sectors as the pharmaceutical industry which is is highly dependent on "complementary assets" such as the advanced engineering, the specialized manufacturing, the complex regulatory pathways, and the specific distribution channels. In order to successfully combine the advances in scientific sector with viable commercial propositions, modern strategic planning must focus explicitly on Business Model Innovation (BMI), as described by Rasmussen and Foss (2014).

This perspective is further validated by Amit and Zott (2012), who conceptualize BMI not only as product or process enhancement, but as the fundamental reconfiguration of an organization's underlying activity systems to systematically create and capture value. In the contemporary pharmaceutical industry, characterized by highly regulated and capital-intensive environment, the capability of understanding and continuously modifying these variables, represents a distinct, higher-order competitive advantage.

Subsequently, a novel business model cannot be operated within traditional highly hierarchical corporate structures, and the organizational architecture must be fundamentally re-engineered to support new mechanisms of value creation and capture (Teece, 2010). However this architectural transition requires the utilization of any available "dynamic capabilities" (Teece, 2007, 2018). Pharmaceutical industry strategic planners have to systematically cultivate the organizational capacity to sense emerging technological shifts (such as precision genomics mentioned above), and exploit these opportunities through resource flexibility and internal structures transformation, capable to overcome any bureaucratic obstacles may emerge under a typical operational model.

To successfully execute this transformation under conditions of extended uncertainty, contemporary pharmaceutical firms increasingly rely on the structural framework of the "Ambidextrous Organization" (O'Reilly & Tushman, 2013). Achieving structural ambidexterity requires business planners to implement and manage two different approaches simultaneously: the exploration and the exploitation of the potential dynamic capabilities. In detail, an "Exploitation" unit is dedicated to maintaining and maximizing the efficiency, the regulatory compliance, and value proposition from the existing, established in pharmaceutical market therapeutic portfolio.

On the other hand, the "Exploration" unit is intentionally decentralized, operating under completely different risk management approach and is designated to promote novel business models without being compromised by the strict financial processes of the core entrepreneurial operation.

Furthermore, as the industry transitions toward value-based care, Business Model Innovation (BMI) in healthcare requires a shift from firm-centric planning to ecosystem-centric environment (Adner, 2006). In the modern health-tech landscape, value proposition can no longer be achieved in isolation and the business model must holistically account for complex, interdependent ecosystem. Consequently, organizational architecture must evolve into an open "environment" capable of rapid integration of any external resources. Representative case studies could be found below.

1.3.1 Servitization and the Patient Journey: The case of UCB Pharma

A "servitization" in business model shift occurs when pharmaceutical product manufacturers undergo transition from simply selling drug products to offering integrated solutions of products and services. Initially motivated by the contemporary demand for value-based healthcare, this novel business model heavily relies on "servitization", where the core biological therapeutic process is enhanced and inextricably linked to digital health platforms, companion diagnostics, and patient-adherence services (Visnjic et al., 2016; Baines et al., 2017).

A real-world paradigm of this "servitized" business model could be found in the case UCB Pharma, which is active within the highly complex therapeutic area of neurology. In detail, apart from the commercialization of anti-epileptic drugs (AEDs), UCB has also engineered a comprehensive, service-oriented ecosystem. In this case, the pharmaceutical company has been involved into various services provision, as the integration of wearable biosensors, development of predictive algorithms, and patient-oriented digital applications. Thus, the active tracking of unpredictable epilepsy seizures in real time was feasible. This continuous digital infrastructure captures longitudinal, high-fidelity Real-World Data (RWD), effectively transforming subjective patient experiences into objective, quantifiable "digital biomarkers" (Goldsack et al., 2019).

However, to successfully operationalize this complex "servitization", the pharmaceutical corporate architecture needs to be fundamentally reconstructed. As Zott and Amit (2008) have highlighted, business model innovation cannot survive within strict traditional R&D segmentation. The contemporary pharmaceutical firms should be oriented toward an ambidextrous organizational design described above, facilitating the creation of highly integrated, cross-functional teams.

Within this modern architecture, traditional molecular biologists and clinical trial managers are required to proactively form the product ecosystem alongside with other specializations as software engineers, data scientists, behavioral psychologists, and health economists. This structural fusion ensures that the digital platform and the pharmacological assets are

developed simultaneously, maximizing the therapeutic's total value proposition prior to market launch.

1.3.2 The "Traditionalist to Specialist" Shift: The Novo Nordisk case.

On the other hand, Novo Nordisk has demonstrated how organizational focus as an independent factor can act as a revolutionary business model. By focusing exclusively on chronic metabolic diseases (as Obesity and Type 2 Diabetes) explained during previous discussions, the company has created a "growth model" through deep regional focus and inter-regional alliances (Nakashima et al., 2023). This specialization generated immense dynamic capabilities, optimizing their manufacturing highly specialized in GLP-1 receptor agonists production, which allows a launch of the pharmaceutical products to the global market at a speed that highly diversified competitors could not compete.

1.4 The Productivity Crisis and "Fail-Fast" Planning

Despite the fact that the capital being invested by the Pharmaceutical companies into research activities has been increased exponentially during the last decades, the Internal Rate of Return (IRR) for R&D has dropped to historic lows (Deloitte, 2025). Consequently, a critical component of any modern business plan must explicitly address robust portfolio pruning, under a strategic approach of evaluating and eliminating underperforming, redundant, or non-core assets within the pharmaceutical sector activities.

1.4.1 Integrated Business Planning (IBP) and Financial Gating

Modern pharmaceutical business planning is heavily focused on systematically terminating flawed opportunities as their early stages, as possible within the development lifecycle. To operationalize this, firms increasingly rely on Integrated Business Planning (IBP) frameworks (Anaplan, 2026) that structurally embed the principles of the Stage-Gate model, formalized by Cooper (2011). In this innovation architecture, the process of drug

development is deliberately segmented into discrete, cross-functional phases (Stages) separated by rigorous, multidisciplinary management decision points (Gates; figure 2).

According to Cooper (2011), an effective gate acts as a strict quality-control checkpoint comprising three elements: required deliverables, defined evaluation criteria, and definitive decision outputs (Go, Kill, Hold, or Recycle) (p. 147). Within the biopharmaceutical context, it is a common practice where clinical developmental milestones are established by the strategic planners such as *in vivo* toxicity assessment or Phase IIa clinical trials proof of-concept, as strict financial "go/no-go" gates. Among the evaluation "checkpoints", an overall assessment is performed by cross-functional portfolio committees, based not only on the pharmaceutical product mode of action and the biological target efficiency, but against strict predetermined pharmacoeconomic metrics, including projected Internal Rate of Return (IRR) and Net Present Value (NPV).

Subsequently, if an asset cannot mathematically demonstrate a projected commercial viability that exceeds the firm's required cost of capital during early-stage evaluation, a definitive "Kill" decision is executed. Instead of proceeding into project termination as a result of a scientific failure or inadequacy, the Stage-Gate model proposes the early "Kill" output as a potential strategic success. By enforcing strict financial gates, the pharmaceutical firms effectively neutralize possible risks for exposure to organizational "sunk cost fallacies" explained above, ensuring adequate R&D resources for pipeline assets that possess a higher probability of successfully meeting the complex regulatory and commercial landscape.

Figure 2: The application of the Stage-Gate model (Cooper, 2011) in pharmaceutical industry



1.4.2 The AI Impact: Digital Twins and In Silico Validation

It should also be highlighted that the successful implementation of the aforementioned Stage-Gate model in the pharmaceutical industry financial structures, is heavily defendant on the profound integration of advanced computational modeling into the early stages of strategic planning. In contemporary pharma operations, the conceptual phase increasingly leverages Model-Informed Drug Development (MIDD) to deploy "Digital Twins", generative AI-powered virtual representations of biological entities, individual patients, and scale-up manufacturing bottlenecks (Bordukova et al., 2023).

Within the clinical environment, these sophisticated algorithms utilize historical genomic and longitudinal Electronic Health Record data (HER; mentioned also in previous chapters) to construct highly realistic virtual patient cohorts, enabling the execution of *In Silico* Clinical Trials (ISCTs; Chen et al., 2025; Viceconti et al., 2021).

By utilizing a "digital twin" approach, business planners and clinical scientists can virtually simulate a novel drug product performance in patient populations to predict real-world efficacy, systemic toxicity, and adverse event profiles long before the first physical dose is administered, allowing also the execution of a "virtual failure" (PwC, 2026). If the *in silico* simulation demonstrates that an asset will fail to achieve statistical superiority over an established, low-cost generic comparator, the commercial opportunity is immediately terminated at the early "gate" or preclinical assessment.

The transitioning form developmental failures on the highly capitalized physical reality of a Phase III trials to an inexpensive computational simulation, the "Digital Twins" approach subsequently lead to a significant financial risk minimization predicted based on the above-described principles of Eroom's Law.

1.4.3 Payer-Ready State and PICO Alignment

Finally, opportunity identification is inherently heavily dependent on the financial capabilities of the patient or the healthcare or insurance institutions. In the European framework, a Joint Clinical Assessment (JCA) under the new EU Health Technology

Assessment Regulation (HTAR) has recently been implemented intending to standardize the clinical evaluation of new medicines and reduce duplicative national efforts by providing a unified, EU-wide clinical evidence base (Main, Schäfer, & Kanavos, 2025). However, while the clinical assessment is centralized in terms of European Authorities evaluation, the individual Member States retain absolute sovereignty over economic evaluations, refunding, claw-back decisions, and final pricing. To navigate this fragmented landscape, a pharmaceutical business plan must proactively and exactly identify the PICO (Population, Intervention, Comparator, and Outcomes) alignment long before clinical trial initiation. The JCA relies heavily on pragmatic PICO scoping to address the diverse standards of care across different European nations.

Furthermore, contemporary market access is increasingly dictated by the absolute macro-economic limits of global healthcare or insurance budgets. The introduction of highly complex health technologies, such as advanced therapy medicinal products and customized biologics described in previous chapters, are characterized by a growth rate which is significantly faster compared to the relevant healthcare financing pace, leading to severe affordability crises and threatening the sustainability of equitable patient access across varying jurisdictions (Kaló et al., 2023).

Under ongoing EU pharmaceutical legislative reforms, the fast and broad availability of affordable medicines across all Member States is heavily incentivized; a failure to launch affordably and equitably in diverse markets can jeopardize a pharmaceutical firm's already established market protections and data exclusivity incentives (Main, Schäfer, & Kanavos, 2025).

Consequently, a successful opportunity identification in a modern pharmaceutical industry environment, is based on the readily early-stage "Price-to-Value" simulations as well as the strategic integration of novel payment models, such as outcomes-based risk-sharing agreements (Kaló et al., 2023). If the projected price required to regain capitalized R&D costs cannot be supported by robust real-world evidence and value-based analyses, the pharmaceutical product is fundamentally unviable and strategically deprioritized. In this ecosystem, the pharmaceutical companies are required to proceed into systematic collaborative value assessments (CVAs) and horizon scanning, so as to ensure market exclusivities and ensure that pharmaceutical pricing structures remain sustainable for the payer (Rintoul et al., 2020).

1.5 Chapter 1 Synthesis: The Paradigm Shift in Conceptual Planning

From all the above mentioned, it is concluded that for the implementation of a modern conceptual planning in the pharmaceutical industry environment a fundamental shift in conceptual terms, is required: the novel molecular substance should be merely considered as a "passenger," where combined factors as regulatory authorities, digital, and market-access elements, should be considered as the "vehicle". The adoption of this perception delivers a significant competitive advantage, as a scientifically viable molecule cannot survive commercialization without a meticulously engineered evidentiary support.

This transition relies on the introduction of Integrated Evidence Plans (IEPs), which obliges various cross-functional teams within the firm to proactively close holistic "value gaps" rather than merely filling regulatory "data gaps" (Olson & Capkun, 2024). By aligning early-stage research with Health Economics and Outcomes Research (HEOR), firms maximize the probability of regulatory approval and significantly enhance the asset's expected Net Present Value (eNPV; DiMasi et al., 2024).

Consequently, the regulatory route is no longer a passive administrative obstacle but a valuable tool to achieve accelerating corporate growth or solve critical constraints. Pharmaceutical industry planners are now directed towards the exploitation of expedited frameworks as the EMA's Priority Medicines scheme (PRIME; mentioned above) targeting the optimization of time-to-market period needed for high-demand therapeutics (Detela & Lodge, 2019).

The defining characteristics of this transition, from traditional discovery to modern strategic pathway engineering, are synthesized in Table 1.4 below:

Table 1.4: The Opportunity Identification Pivot

Element	Traditional Identification ("The Passenger")	Modern Identification ("The Vehicle")
Primary Focus	Intrinsic novelty of the chemical structure.	Architecture of the Integrated Evidence Plan (IEP) and regulatory pathway (Olson & Capkun, 2024).
Evidence Goal	Filling "data gaps" to prove clinical efficacy.	Closing "value gaps" through real-world comparative effectiveness and HEOR (DiMasi et al., 2024).
Regulatory Target	Standard, linear approval for mass markets.	Expedited regulatory routes (e.g., PRIME) for targeted applications (Detela & Lodge, 2019).
Primary Risk	Late-stage (Phase III) scientific failure.	Post-market access failure due to unaffordability or HTA rejection.
Digital Role	Passive documentation and data storage.	Active deployment of "Digital Twins", *In Silico* trials, and Real-World Evidence (RWE).

2. Chapter 2: Strategic Exploitation through Alliances and AI

In Chapter 1, was described the process where a business model proposal and subsequently the opportunity identification in pharmaceutical industry is characterized by the acceptance that a successful validation of a potential biological target represents only the initial phase of the innovation lifecycle. The major organizational challenge in pharmaceutical ecosystem refers to the strategic management exploitation, which necessitates the mobilization, and alignment of specialized resources required to fulfill an increasingly stringent regulatory and pharmacoeconomic requirements (Teece, 2007).

Driven by the increased complexities of systems biology and specific mode of action of the novel pharmaceutical products, as well as and the financial restrictions delivered by the application of Eroom's Law described above, the fundamental mechanism of this exploitation has undergone a profound structural redefinition. Dissociated from previous traditional and vertically structured hierarchies, characterized by isolated research and development (R&D) activities, contemporary firms increasingly operationalize the principles of "Open Innovation" (Chesbrough, 2003). In this case, the developmental procedures are now externalized by deeply integrating highly specialized, Artificial Intelligence (AI)-driven digital ecosystems (Jayatunga et al., 2022). Consequently, business development and external partnering are no longer treated as supplemental support activities, but as core corporate capabilities essential for scaling growth (Lubkeman et al., 2021).

Subsequently, value creation within the pharmaceutical sector has now been expanded beyond proprietary chemical assets to include the firm's capacity to orchestrate algorithmic networks and computational capital (Iansiti & Lakhani, 2020).

2.1 The Paradigm Shift: From Intellectual Property to Computational Capital

Historically, the enterprise valuation of a biopharmaceutical firm was dictated by two static asset classes: the physical capital (manufacturing infrastructure and R&D laboratory premises) and intellectual capital (proprietary chemical structures protected by patent law).

Within the traditional theoretical framework of the Resource-Based View (RBV) of the firm (Barney, 1991), these specific assets were heavily prioritized by business planners because they fulfilled the criteria for a sustained competitive advantage: they were highly valuable, rare, and significantly difficult for competitors to imitate without been subjected to prohibitive capital expenditures. Consequently, a pharmaceutical firm's market dominance was fundamentally supported by the corporate size and the overall exclusivities and legal protection of its patented molecules and products.

However, under contemporary market pressures, the reliance on these static asset is subjected to various strategic limitations, as both physical and traditional intellectual capital are inherently susceptible to predictable depreciation process. Physical manufacturing sites require a continuous and intensive capital expenditure to maintain competence and compliance with evolving Good Manufacturing Practice (GMP) standards. In addition, the intellectual capital is characterized by time restrictions, as patent expiration or Loss of Exclusivity (LOE) inevitably leads to a revenue decline.

In response to the economic pressure predicted by the Eroom's Law pronciples, modern pharmaceutical business planning has executed a structural shift toward the accumulation of "Computational Capital". Computational capital is defined as the proprietary, synergistic integration of a firm's algorithmic capabilities, digital infrastructure, and harmonized data assets. Unlike physical or intellectual capital, computational capital is currently consisting of a separate asset class. In this case, the "Computational Capital" utilizes the "data network effects", a phenomenon where machine learning architectures intrinsically improve in predictive accuracy and systemic efficiency as they ingest longitudinal biological data (Iansiti & Lakhani, 2020). Consequently, any successful or failed clinical trial, mathematically enhances the firm's algorithmic database, ensuring that the next target identification will be progressively faster and less resource demanding. Therefore, the application of these advanced AI platforms by the contemporary pharmaceutical firms leads to the acceleration of novel pharmaceutical substances discovery and minimization of the inherent clinical studies risk. As an example, in terms of conventional pharmaceutical approach, an oncology asset could not deliver any clinical or commercial utility in other medical sectors, as rheumatology. However, under a computational capital framework, the underlying algorithmic infrastructure is universally applicable across different therapeutic areas.

Case Study: The mRNA "Operating System" of Moderna.

A representative example of "Computational Capital" application in pharmacoeconomic business model, could be found in the case of Moderna pharmaceutical industry. Unlike other dominant pharmaceutical firms, Moderna's foundational business plan was not based on the development and market launch of a single biologic compound. Instead, the firm actively refers to its mRNA technology as the "Software of Life," effectively treating their proprietary *in silico* sequence generators and lipid nanoparticle (LNP) delivery platforms as an algorithmic operating system (Bancel, 2021). In this case, new therapeutic compounds can be rapidly coded and integrated into the corporate platforms, under the same approach of downloading a new application on a computerized system. This computational capital approach allowed Moderna to rapidly engineer the SARS-CoV-2 vaccine sequence bypassing completely the elongated trial-and-error processes that conventional chemistry requires for a traditional vaccine development.

Case Study: AI-based Externalization of Sanofi and Exscientia.

For established pharmaceutical companies that have not developed internal computational infrastructure, this capability could be acquired through the formation of strategic alliances. A representative example is Sanofi's multi-billion-dollar alliance with the AI-driven pharmatech firm Exscientia. Insead of purchasing a specific drug substance at a late-stage of development, Sanofi decided to invest in the acquisition of computational capability, utilizing Exscientia's end-to-end AI platform. This alliance ultimately led to the discovery up to 15 novel small-molecule candidates across oncology and immunology (Jayatunga et al., 2022). This collaboration illustrates the modern exploitation strategy, where established firms invest capital resources and experimental raw data available through years of operation, acquiring external computational capital targeting a horizontally scalable, AI-enabled ecosystem.

2.2 Open Innovation and the Shift to "Agentic" R&D Ecosystems

The foundational principle regulating modern pharmaceutical exploitation is described in Chesbrough's (2003) model of Open Innovation. After recognizing that the highly interactive, non-linear complexity of modern systems biology could exceed the internal capabilities of any single corporate R&D department, various established pharmaceutical industries have repositioned from the traditional vertically structured innovation frameworks, to the adaptation on advanced methodologies of emerging biotech spinoffs, (Schuhmacher, Gassmann, & Hinder, 2016).

As Lubkeman et al. (2021) emphasize, business development and external partnering are no longer considered as supplementary functions, but rather core corporate competencies that are absolutely essential for enterprise growth. At current age, the nature of these open alliances has undergone a profound digital transformation. The integration of artificial intelligence and machine learning into drug discovery has evolved significantly beyond early, isolated applications (Vamathevan et al., 2019). The pharmaceutical industry is currently subjected to a fundamental transformation, from "Task-AI" systems strictly constrained to descriptive data analysis or single-variable statistical predictions, to an overall comprehensive "Agentic AI".

Current agentic AI ecosystems are characterized by autonomous, algorithmic base capabilities, as proved to be capable of executing highly complex, end-to-end R&D related operations independently (Iansiti & Lakhani, 2020). Furthermore, within these advanced alliances, the deployment of generative artificial intelligence further facilitates the effective "Digital Twins" formation, explained in previous sections (Bordukova et al., 2023 Consequently, modern era open innovation also includes the horizontally scalable, AI-enabled operating systems that accelerate the entire developmental process (Jayatunga et al., 2022).

Case Study: Eli Lilly's TuneLab

A premier demonstration of this epistemological shift toward agentic ecosystems is Eli Lilly's strategic transition to a "Platform-as-a-Partner" model through its TuneLab infrastructure (Ardigen, 2025). Rather than engaging in traditional licensing the adoption of this framework hasallowed external biotechnology partners to directly gain access and utilize Lilly's proprietary, highly advanced AI models. This structural arrangement represents a synergistic and highly leveraged, bidirectional application of Open Innovation (Chesbrough, 2003). Within this integrated ecosystem, the core pharmaceutical enterprise extracts value by exploiting the external partner's innovation and early-stage molecular discoveries, while the biotech partner concurrently utilizes the established firm's advanced computational capital to drastically accelerate its developmental and optimization timelines.

Case Study: Autonomous Regulatory Submissions and Agentic operations

Beyond molecular discovery, the application of Agentic AI has fundamentally redefined the late-stage R&D operations, particularly within the highly intensive human resource domain of regulatory affairs. Contemporary literature has highlighted a critical transition where AI systems autonomously execute comprehensive R&D activities, such as the generation of regulatory submissions (Narrativa, 2026). Instead of relying on manual, sequential data compilation by human regulatory personnel, specialized agentic platforms can now compile raw clinical trial datasets, autonomously prepare draft complex Clinical Study Reports (CSRs), and verify the compliance of output with various international regulatory guidelines that are effective, in real time. This capability not only compresses the operational time, but also mathematically minimizes the probability of human error in critical compliance documentation (Narrativa, 2026).

Case Study 3: De Novo Molecular Design and Algorithmic Optimization: Merck KGaA and Atomwise

Another representative example of externalized algorithmic optimization involves the strategic involvement of AI platforms for *de novo* molecular designs. Facing the inherent limitations of traditional target-based drug discovery, various major pharmaceutical firms have resorted to an increased use of Open Innovation, in order to access hyperscale computational platforms capable of autonomous predictive modeling (Boston Consulting Group, 2025). Within the use of these agentic ecosystems and the utilization of advanced machine learning architectures highly complex biological assessments could be autonomously executed. This includes operations as the *de novo* protein folding predictions as well as advanced pharmacokinetic modeling, which are evaluated *a priori* before any physical synthesis occurs. By integrating these external computational engines, established pharmaceutical firms can actively model biological interactions against disease-related proteins which could not previously be targeted by conventional medicines, under a completely *in silico* environment (Capgemini, 2025)..

For this purpose, a strategic partnership has been established between the pharmaceutical multinational Merck KGaA and Atomwise, a preclinical pharmaceutical company that uses artificial intelligence to discover and design new medicines. By deploying Atomwise's proprietary AI technology, specialized in deep convolutional neural networks to model atomic interactions (Atomwise, 2025), Merck KGaA successfully repurposed this specific intelligence also to predict the binding affinity of small molecules to complex protein structures. Unlike conventional methods requiring time-intensive, physics-based simulations, the Atomwise's proprietary AI system autonomously scans numerous of molecular structures, prioritizing candidates based on high-probability binding predictions before a single compound is physically synthesized in the laboratory.

2.3 Alliances as "Data-Maturity" Bridges

However, it needs to be highlighted that for the effective exploitation of strategic capabilities that the artificial intelligence delivers to the contemporary pharmaceutical industry, a significant challenge consisting of the inherent epistemological distance between theoretical computational predictions and the *in vivo* biological performance, must be conquered.

2.3.1 The Strategic Mechanism of "Data-for-Discovery" Alliances

As a part of solution, strategic alliances between established pharmaceutical firms and highly specialized AI-native startups and hyperscale cloud providers strategic alliances are formed, functioning under a common "Data-for-Discovery" approach. In this case pharmaceutical raw or collected data are purposefully curated, organized, and shared among the organizations, so as to help researchers uncover new insights, build predictive models, and make new scientific or business discoveries. This symbiotic correlation allows the acquired internal corporate data and algorithms to be successfully operationalized from all participants involved, under the FAIR (Findable, Accessible, Interoperable, and Reusable) principles approach (Wilkinson et al., 2016). In this contemporary ecosystem, any absence of this foundational bridge, would result to an inability of advanced AI platforms to process the fragmented R&D analysis data, usually distributed across the Laboratory Information Management Systems (LIMS) and electronic health records (EHRs) databases.

2.3.2 The Epistemological Necessity of Data Harmonization

The transition of contemporary pharmaceutical industry ecosystem towards the FAIR data standards compliance mentioned above, requests an "Industrialization of Intelligence" procedure, where data quality is prioritized as a potential competitive asset. Recent literature establishes that this shift is essential for addressing the persistent lack of reproducibility

issues that has hindered the pharmaceutical R&D productivity for decades. Studies indicate that despite significant advancements in experimental technologies and methodologies, the reliability of findings remains compromised by inconsistent data processing, technical variability, and the use of poorly validated disease models (Scannell & Bosley, 2016; Resnik & Shamoo, 2016).

By prioritizing the harmonization of data, the contemporary pharmaceutical firms can effectively mitigate these systemic failures, addressing also the distance between proprietary biological archives and modern computational tools (Scannell & Bosley, 2016). This integration transforms already available raw data into highly accurate and reproducible input for generative AI models. As this capability escalated within the firm structure, a self-powered virtuous circle is generated. In detail, this capability is scaled and capitalized under a "data network effect," a concept popularized by Iansiti and Lakhani (2020). In this case, the accumulation and integration of proprietary data improve the performance of algorithmic models, creating a self-reinforcing cycle of innovation and competitive advantage (Iansiti & Lakhani, 2020; Figure 3).

Figure 3: Simplification of the "data network effect" cycle in pharmaceutical innovation (Iansiti & Lakhani, 2020)



Case Study: The Biopharma-AI Swap (Novartis and Monte Rosa Therapeutics)

This dynamic is demonstrated in the case of Novartis's recent licensing agreement with Monte Rosa Therapeutics, a strategic partnership finalized in late 2025 and estimated to be valued at a level of approximately $5.7 billion. The alliance is specifically focused on the discovery and commercialization of "molecular glue degraders" (MGDs) for immune-mediated diseases.

In brief, these molecules represent a transformative advancement in targeted protein degradation (TPD), functioning as monovalent small molecules that facilitate the destruction of disease-causing proteins by repurposing the cell's natural protein homeostasis machinery (Cheng et al., 2026; Sasso et al., 2022).

Within this framework, Novartis provides numerous harmonized historical datasets and global clinical development capabilities, where in exchange, Monte Rosa is providing its QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform, which consists of a highly specialized, agentic AI-design engine capable of identifying previously inaccessible protein surface structures (Monte Rosa Therapeutics, 2025).

Case Study: Cloud computing (hyperscaler) Enterprise Integration (Novo Nordisk and Microsoft/OpenAI)

Beyond partnering with specialized biotechs, pharmaceutical business planners are increasingly forming alliances with established computing companies (hyperscalers) that are capable of providing massive cloud capabilities facilitating scalable, enterprise-level computing, storage, and networking services.

A representative example of this strategy is Novo Nordisk's 2026 enterprise-wide partnership with Microsoft Azure and OpenAI (Healthcare Digital, 2026). By this collaboration, a critical strategic target is achieved concerning the data maturity required to transform unstructured archives into actionable computational capital. For this purpose, Novo Nordisk co-developed with Microsoft enterprises a unified, end-to-end data ecosystem that harmonizes fragmented R&D data into a centralized, standards-aligned architecture ((Microsoft, 2026). By directly applying advanced machine learning tools, the researchers have transitioned from manual, time-intensive workflows to the engineering of

predictive algorithms capable of forecasting complex cardiovascular risks with greater accuracy than traditional clinical standards.

This integration effectively triggers a "data network effect," as described by Iansiti and Lakhani (2020), where the systematic accumulation and harmonization of proprietary knowledge improves the algorithmic performance and subsequently reinforcing the operational capabilities into active competitive assets (IntuitionLabs, 2026).

2.4 AI in Clinical Exploitation: Reducing Trial Complexity

While artificial intelligence has accelerated target identification, the most profound pharmacoeconomic exploitation occurs during the clinical trial phase, where the industry's typically observed 90% failure rate in clinical studies are resulting to a $2.6 billion capitalized R&D cost-to-market DiMasi,et al., 2016, Scannell, et al., 2012; Waring et al., 2015).

To mitigate this systemic inefficiency, pharmaceutical planners are shifting toward uncertainty reduction strategies, utilizing computational platforms to transition from coincidental discovery to deliberate engineering. As portfolios are increasingly managed through these predictive frameworks, pharmaceutical enterprises are evolving into "Tech-Bio Hybrids," prioritizing the ability to accurately forecast clinical outcomes and terminate inadequate assets early in process, as a core competitive capability.

2.4.1 Agentic AI in Patient Matching and Recruitment

Apart from the critical factors described in the previous paragraphs, the successful clinical studies recruitment consists of a major operational perquisite. Historically, up to 80% of clinical trials fail to meet enrollment timelines due to inefficient, manual matching methods that struggle to interpret the observed differences in complex patient medical histories (Lu et al., 2024).

Advanced Large Language Model (LLM) platforms, such as TrialGPT, mitigate this bottleneck by performing real-time assessment of unstructured Electronic Health Records (EHRs) and highly complex trial eligibility criteria (Coherent Solutions, 2026). Empirical evaluations demonstrate that such agentic AI frameworks achieve criterion-level matching accuracies of 87.3% and systematically reduce patient screening times by over 42.6%, radically accelerating trial initiation and reducing operational overhead without compromising data integrity (Jin et al., 2023).

Furthermore, the application of these contemporary models also proved to provide more contextually accurate candidate identification, demonstrating a possible potentiality for fully autonomous recruitment engines (Li et al., 2025).

2.4.2 Virtualization via *In Silico* Clinical Trials (ISCTs)

As also been mentioned previously, strategic planners are increasingly deploying the "Digital Twins approach through the regulatory framework of Model-Informed Drug Development (MIDD) for the progression from physical to virtual validation (Bordukova et al., 2023). These *in silico* Clinical Trials (ISCTs) allow business planners to virtually simulate the drug administration in diverse patient populations, as generative models capture population variability and predict an asset's efficacy and adverse event profile before an expensive physical Phase III trial is initiated (Chen et al., 2025; Viceconti et al., 2021).

Advanced methodologies, such as TwinRCTs, leverage historical prognostic data to accurately simulate individual disease extrapolation, allowing firms to mathematically achieve sophisticated clinical studies with significantly smaller physical control requirements, reducing the logistical complexity of traditional randomization as well as rise of possible ethical concerns (Terranova & Venkatakrishnan, 2024).

Furthermore, standardizing these *in silico* workflows using nonlinear mixed-effects models provides robust uncertainty quantification, ensuring these virtual trials meet stringent regulatory evaluation standards (Cortés-Ríos, 2025; Viceconti et al., 2021). Ultimately, if the *in silico* simulation demonstrates that an asset will fail to show clinical superiority over an established generic comparator, the commercial opportunity is terminated before significant physical capital is lost (Bordukova et al., 2023).

2.4.3 Economic Synthesis and Productivity Gains

The integration of these AI-driven simulated performance frameworks is fundamental to reversing the pharmaceutical industry's productivity crisis, previously predicted in the pharmacoeconomic principles of Eroom's Law. Industry reports consistently indicate that these advanced technologies, including predictive modeling and digital twins application, could significantly reduce the overall development timelines for a novel pharmaceutical product, from traditional 10–12 years down to 5–7 years, yielding a 15–22% reduction in the average capitalized cost per approved therapeutic (IQVIA, 2025).

Furthermore, as also been previously discussed, the early identification of non-viable molecules early could prevent the significant financial losses associated with unsuccessful late-stage Phase III clinical trials (Waring et al., 2015; Bordukova et al., 2023). Ultimately, these virtualized methodologies allow firms to achieve a structural improvement in the probability of technical and regulatory success (PTRS) (Deloitte, 2025), systematically maximizing the expected Net Present Value (eNPV) of their innovation pipelines before physical capital is depleted (DiMasi et al., 2024; PwC, 2026).

2.5 Governance as a Competitive Advantage

In the contemporary strategic landscape, the speed of algorithmic exploitation is strictly bounded by regulation procedures and frameworks established by various health Authorities, most notably the EU Artificial Intelligence (AI) Act. As highlighted by the European Federation of Pharmaceutical Industries and Associations (EFPIA; 2026), algorithmic governance is not considered as a peripheral post-development compliance factor but a foundational design asset necessary for an early market access.

The classification of most life sciences AI as "high-risk" under the EU AI Act necessitates the systematic integration of "Human Oversight," "Data Quality and Transparency," and comprehensive "Auditability" protocols into the R&D architecture. As proposed by Mökander et al. (2022), this three-layered auditing approach effectively transforms

regulatory compliance into a distinct competitive advantage, ensuring that a firm's AI-driven innovation is both legally compliant and commercially sustainable.

2.5.1 The Mandate of Auditability and Data Integrity

Pharmaceutical industry modern business planning has nowadays incorporated the systematic integration of "Auditability" and "Traceability" principles into AI-driven alliances even at their early stages. Proprietary algorithms must strictly comply with strict Good Laboratory and Manufacturing Practices (GxP) as well as the ALCOA+ (Attributable, Legible, Contemporaneous, Original, and Accurate) data integrity principles. This requirement reflects a broader regulatory shift toward "Explainable AI" (XAI), where the underlying decision-making logic of algorithmic systems must be accessible, transparent and verifiable by regulatory Authorities (Mökander et al., 2022).

Pharmaceutical firms that proactively deploy transparent, heavily audited models can be awarded under a regulatory prioritization, operating significantly faster than competitors that may rely on non-transparent machine learning systems that may face delays or rejection under the stringent evaluation of the EU AI Act (Vokinger & Gasser, 2021).

Case Study: AstraZeneca and CSPC Pharmaceuticals

The operational necessity of these protocols is evidenced in the case of AstraZeneca's 2025 alliance with CSPC Pharmaceuticals (AstraZeneca, 2025). While the partnership was initially formed on the basis of AI-generated algorithms for small-molecule discovery, the firm's business plan requested the inclusion of embedded "automated validation" protocols to ensure that all algorithmic outputs were entirely regulatory-ready from the outset (AstraZeneca, 2025). By designing the alliance to enforce GxP-compliant data logging directly within the AI discovery architecture, the firms effectively minimized the post-development algorithmic validation requirements that typically decelerate AI-driven drug discovery projects (Epthinktank, 2026; Mökander et al., 2022; Vokinger & Gasser, 2021).

2.6 Chapter 2 Synthesis: Strategic Exploitation Mechanisms

The transition of the pharmaceutical industry towards the adoption and implementation of dynamic, AI-driven computational networks represents the most significant shift in modern business planning. As explained throughout this chapter, the commercial viability of a modern pharmaceutical opportunity is no longer determined by the isolated success of a chemical entity, but by a firm's organizational capacity to integrate external computational capabilities with internal biological databases.

The mechanisms summarized in Table 2.1 demonstrate that the exploitation of innovative drug products is now a multidimensional requirement. By operationalizing "Platform-as-a-Partner" alliances, establishing " Data Harmonization" procedure and enforcing effective algorithmic governance, contemporary firms systematically mitigate any inherent risks within their portfolios. These strategic decisions are capable to transform R&D procedures from a high-risk, "random walk" methodologies into a constructed, autonomous, and scalable pathway for value creation.

Table 2.1: The Mechanisms of AI-Enabled Strategic Exploitation

Exploitation Lever	**Strategic Focus & Mechanism**	**Commercial Enactment & Outcome**
Agentic AI Integration	Transitioning from descriptive "Task-AI" to autonomous execution of R&D workflows (e.g., regulatory documentation, target design).	Accelerates time-to-market; autonomously drafts regulatory dossiers and optimizes pharmacokinetic modeling to minimize human error.
Platform-as-a-Partner	Providing proprietary AI infrastructure (e.g., Eli Lilly/TuneLab) to external	Generates horizontally scalable value across the pipeline rather than relying on

	partners to identify and optimize novel molecular discoveries.	a singular, vertically integrated asset.
Necessity for Data Harmonization	Harmonizing legacy "dark data" stacks via FAIR ontology (Findable, Accessible, Interoperable, Reusable) to feed generative AI models.	Eliminates the "Bio-Digital Gap," extracting actionable commercial value from decades of historical R&D trial failures.
Clinical Trial Virtualization	Deploying Digital Twins and Model-Informed Drug Development (MIDD) to virtually validate efficacy and safety before physical dosing.	Drastically reduces clinical trial complexity; "fail-fast" simulations reduce overall capitalized R&D costs by 15–22%.
Algorithmic Governance	Embedding ALCOA+ data integrity and transparency directly into AI discovery architectures (e.g., AstraZeneca/CSPC).	Transforms compliance into a competitive advantage, allowing transparent, audited models to rapidly clear EU AI Act regulatory pathways.

3.Chapter 3: Navigating Barriers—The Patent Cliff and Pricing

The ultimate efficacy of biopharmaceutical business planning is not exclusively determined by regulatory approval, but fundamentally depends on the organization's Dynamic Capability to continuously reconfigure its assets across the product lifecycle (Song & Lee, 2016; Teece, 2007).

This terminal phase of opportunity exploitation necessitates that pharmaceutical enterprises proactively navigate complex economic pressures and aggressive competitive forces that inherently jeopardize long-term commercial viability (Gautam & Pan, 2016).

It should be highlighted that among the most critical existential vulnerabilities is the statutory expiration of intellectual property rights and market exclusivity. This situation is formally classified as Loss of Exclusivity (LOE) and is widely recognized under the terminology of 'Patent Cliff', which constitutes the most profound structural challenge to the sustained profitability of established biopharmaceutical organizations (Song & Lee, 2016).

In order to safeguard commercial value, modern firms must shift from defensive protection to proactive Ecosystem Management. This activity requires the alignment of a complex network of stakeholders, including institutional payers, diagnostic providers and manufacturing partners, so as to sustain the asset's competitive positioning (Adner, 2006).

Operating under this framework, lifecycle management is operationalized through Servitization (Baines et al., 2017) and the pharmaceutical products are no longer procured as standalone commodities but are integrated into comprehensive healthcare service ecosystems. This approach allows the transformation of a therapy from a drug administration to an essential, longitudinal clinical utility.

Consequently, this chapter analyzes how contemporary firms employ these theoretical pronciples to engineer 'Strategic Switches,' value-based performance agreements, and sustainable supply chains, finally achieving a separation of the asset's commercial lifecycle from its original statutory patent expiration date.

3.1 The Epistemology of Value Protection

Historically, the transition from an innovative, protected status to a latter market characterized by generic commodities, was widely accepted as a terminal event in a product's lifecycle. However, contemporary strategic management literature (Song & Lee, 2016) propose that this phase requires a fundamental shift from the current defensive product protection to a proactive dynamic lifecycle management.

Within the current biopharmaceutical landscape, this transition is increasingly complex; as the severe revenue depletion, associated with small-molecule patent expiration is now followed by intensified skepticism by institutional payers as the global healthcare or insurance organizations, as well as an aggressive regulatory trend to incentivize biosimilar drug products adoption (Grabowski & Long, 2011). Consequently, modern business planning must be inherently iterative, where strategic plans are treated as continuous, evolving frameworks rather than rigid, one-time documents. Subsequently, it is of critical importance modern pharmaceutical firms to predict and operationalize a "post-patent" status even during the early pre-clinical development phases, where any possible failure at this process would inevitably lead to a serious corporal financial deficit.

This potential revenue loss directly inhibits the continuous capital reinvestment process, which is required to counteract the systemic R&D productivity decline, as has been defined in Eroom's Law principles (Scannell et al., 2012). Subsequently, the primary objective of this final exploitation stage is to reposition from the current singular molecular protection approach, towards engineering a resilient, multi-modal architecture. By adopting this approach, the asset's clinical value proposition and its original statutory expiration date, will be effectively decoupled (Song & Lee, 2016).

For this purpose, on this chapter will be discussed how modern pharmaceutical enterprises deploy strategic switches, value-based contracting, and sustainable supply chain organization in order to develop and sustain commercial dominance within a highly competitive, post-exclusivity global market.

3.2 Multi-Modal Lifecycle Management and demonstration of Dynamic capabilities (Strategic Switches)

The expiration of market exclusivity (previously also described as "Patent Cliff") represents a catastrophic revenue erosion event for the originator pharmaceutical firms (Song & Lee, 2016). Upon the loss of patent protection, the rapid market entry of generic or biosimilar drug products could lead to a decrease up to 90% of the originator's market share even at a very short period. This financial decline is heavily accelerated by statutory "automatic substitution" policies implemented across various healthcare systems and Authorities worldwide, which legally mandate the distribution of the lowest-cost therapeutic equivalent in an effort to restrict the pharmaceutical expenditures (Danzon & Furukawa, 2011; Grabowski & Long, 2011). Consequently, contemporary pharmaceutical business planning can no longer rely on static commercialization models, and in order to sustain a long-term commercial viability, strategic planners are requested to adopt a systematically proactive, repetitive framework of Multi-Modal Lifecycle Management (Song & Lee, 2016). In detail, it is required a demonstration of "Strategic switch" as a clear manifestation of company's dynamic capabilities, in order to maintain the pharmaceutical asset's value proposition before the market degrades the original business model.

3.2.1 The Evolution from Defensive Evergreening to Value-Added Strategy

Following the theoretical framework established by Song and Lee (2016), modern pharmaceutical business planning has evolved significantly beyond the traditional implementation of isolated "Strategic Switches", expressed as the the adoption of targeted, standalone pivots in how the organization, operates. Historically, pharmaceutical originator companies relied mostly on defensive tactics to artificially extend their market exclusivity and patent monopolies ("evergreening" strategies). This practice was often characterized by superficial product modifications, such as reformulating a standard solid oral dosage into an

extended-release variant, primarily aimed at securing secondary patents and extending statutory monopolies.

However, within the contemporary healthcare ecosystem, such incremental tactical moves are now seriously challenged by modern Health Technology Assessment (HTA) bodies and healthcare and insurance institutional payers. In detail, there is an increasing rate of denials to grant or sustain reimbursements for pharmaceutical formulations that fail to demonstrate statistically significant improvements in clinical utility, comparative effectiveness, or overall patient outcomes (Eichler et al., 2016; Kaló et al., 2023).

To successfully overcome these stringent value-based reimbursement requirements, strategic planners have transitioned toward the adoption of a Multi-Modal Lifecycle Management perspective. This comprehensive approach inherently focuses on continuously enhancing the asset's holistic value proposition through rigorous, evidence-based clinical differentiation and substantive delivery innovation throughout the product's market lifespan (DiMasi et al., 2024; Song & Lee, 2016).

3.2.2 The "Rolling Exploitation" Strategy: The Case of Keytruda (Merck).

A definitive manifestation of contemporary Multi-Modal Lifecycle Management is demonstrated in the revenue operations of the commercially successful immunotherapy Keytruda (pembrolizumab) by Merck. The firm's strategic planning exemplifies a "rolling exploitation" paradigm, designed to systematically transition the therapeutic market towards next-generation delivery formulations in view of anticipated patent expirations (Song & Lee, 2016). As the foundational patents protecting the original intravenous (IV) formulation was near its Loss of Exclusivity (LOE) deadline, Merck has strategically initiated a market migration towards novel subcutaneous (SC) formulations and advanced clinical combinations, frequently driven by continuous, targeted indication expansions (Heine et al., 2024; Rome et al., 2021).

This tactical shifting substantially exceeds the typical evergreening practices and it constitutes a meticulously calculated "Strategic Switch" that simultaneously optimizes patient adherence and clinical convenience. In detail, the previously applied prolonged hospital infusions are now replaced with rapid subcutaneous administration, while

effectively extending the asset's market exclusivity through novel delivery mechanism patents (Song & Lee, 2016).

By proactively elevating the clinical standard of care before biosimilar competitors can establish a viable generic drug product, Merck successfully achieved to ensure that the asset's long-term commercial relevance remains securely embedded within a proprietary, value-added healthcare ecosystem.

3.2.3 Formulation Complexity and Servitization: The Case of LAIs (Invega and Cabenuva)

An additional effective manifestation of the "Strategic Switch" approach and a definitive approach for "patent cliff" avoidance, is also the contemporary engineering of Long-Acting Injectables (LAIs). Unlike the Keytruda paradigm, which relies on clinical indication sequencing, LAI commercialization protects the asset's value through extreme formulation complexity and the "servitization" of the delivery mechanism (Baines et al., 2017; Song & Lee, 2016). In detail, the "servitization" process refers to the transition that a novel pharmaceutical company in undergoing, where the commercial value is captured through the delivery mechanism itself rather than just the active ingredient administration.

Janssen Pharmaceuticals' lifecycle management of paliperidone palmitate (Invega) exemplifies this rolling exploitation strategy within the psychiatric domain, and specifically the treatment of schizophrenia and schizoaffective disorder. By systematically migrating the patient base from a daily oral administration as a tablet finished product form, to a one-month LAI (Invega Sustenna), subsequently to a three-month (Invega Trinza), and ultimately to a six-month formulation (Invega Hafyera), the firm effectively neutralized the threat of generic substitution (Song & Lee, 2016; Figure 4).

Because the engineering process of the drug product formulation is exceptionally difficult, requiring a specific nanocrystal suspension in order to achieve a controlled, 180-day pharmacokinetic release profile, biosimilar and generic manufacturers face prohibitive technical issues to reverse-engineer and proving bioequivalence similarity. In parallel, ViiV Healthcare's introduction of Cabenuva (cabotegravir and rilpivirine) fundamentally reconfigured the business model of HIV management by transitioning treatment also from

a daily oral tablet to a bimonthly intramuscular injection (a clinical medical benefit as in the case of Invega above). In strategic management literature, this shifting represents a highly successful pivot towards "servitization" (Baines et al., 2017; Visnjic et al., 2016).

By converting a traditional pharmaceutical product into an integrated, clinic-administered service, the manufacturer guarantees elongated patient adherence, while establishing a proprietary delivery ecosystem that generic competitors cannot legally or logistically substitute at the retail pharmacy counter (Teece, 2010).

Figure 4: Pharmacokinetic profiles of daily oral versus 6-month LAI administration



3.3 The Pricing and Access Crisis: From Price to Value-Linkage

Even in the case where a biopharmaceutical company successfully safeguards its intellectual property via robust, effective and multidimensional lifecycle management, various challenges could be raised when targeting a sustainable reimbursement acquisition. The pharmaceutical industry is currently facing a systemic macroeconomic barrier, explicitly characterized in recent pharmacoeconomic literature as the global "ceiling of affordability" (Vallano et al., 2024).

As operating under a constrained financial ecosystem, a pharmaceutical business plan designated to achieving regulatory clinical success and scientific excellence without

proactively resolving any potential fiscal limitations of global healthcare budgets, could be considered as fundamentally unviable (Eichler et al., 2016; Kaló et al., 2023). As a direct consequence, the commercialization architecture has irreversibly been transitioned towards commercial models adoption, where corporate financial returns are directly linked with empirically measurable, real-world patient outcomes and comprehensive health economic value (Drummond et al., 2024; Vallano et al., 2024).

3.3.1 Evidence-Based Market Access and Performance Agreements

To effectively commercialize and exploit highly priced, innovative therapeutic opportunities, global institutional payers, as private insurance consortiums to healthcare systems, are currently demanding the explicit mitigation of both clinical and financial uncertainty (Vallano et al., 2024). This is predominantly achieved through the systemic implementation of a process described as Outcome-Based Risk-Sharing Agreements (OBRSAs; Carlson et al., 2017). The OBRSAs implementation function as sophisticated mechanisms designed to bridge the inherent informational asymmetry that exists between the pharmaceutical manufacturer and the payer at the precise moment of market launch (Garrison et al., 2015).

Subsequently, for a modern pharmaceutical business that plans to remain economically viable under the aforementioned strict financial conditions, it should proceed into the incorporation of a robust, proprietary Real-World Evidence (RWE) generation mechanism. This architectural requirement requires the systematic integration of digital health technologies, interoperable electronic health records (EHRs), and continuous patient monitoring (Miksad & Abernethy, 2018).

These infrastructures are critically utilized to empirically validate the therapeutic's ongoing efficacy within heterogeneous patient populations, moving beyond the highly controlled, artificial confines of traditional Phase III clinical trials (Franklin et al., 2019). Ultimately, the pharmaceutical enterprises are now continuously requested to justify their premium pricing tiers through rigorous post-market data collection, actively absorbing and sharing the financial liability of therapeutic non-responders with the broader healthcare system (Garrison et al., 2015; Kaló et al., 2023).

3.3.2 The Zolgensma Paradigm: Annuities and Outcome Guarantees

The absolute necessity of this value-based approach could be exemplified in the case of the commercialization of Zolgensma (onasemnogene abeparvovec) pharmaceutical product. This consists of a transformative *in vivo* gene therapy indicated for spinal muscular atrophy (SMA), that causes the progressive loss of motor neurons in the spinal cord. Introduced as a high-cost, potentially curative single-dose administration, the asset was inevitably exposed to the structural limitations of traditional healthcare financing system.

These institutions, inherently designed to mitigate chronic, incremental therapeutic expenditures, were fundamentally unable to accommodate such a costly pharmaceutical asset, despite the presence of various indications on therapy's exceptional, lifetime "cost-effectiveness" projections (Drummond et al., 2024). Consequently, the successful commercial exploitation of this advanced therapy medicinal product (ATMP) was exclusively achieved through the architectural implementation of innovative, annuity-based payment models paired with strict clinical outcome guarantees (Carlson et al., 2017; Drummond et al., 2024). Under this risk-sharing framework, the increased capitalized cost of the therapy is systematically distributed over a multi-year horizon. Furthermore, a sustained reimbursement procedure by the institutional payer requires the patient achieving and maintaining predefined, objective clinical milestones such as specific motor function achievements. Contemporary pharmacoeconomic literature highlights that similar performance-based agreements between the pharmaceutical enterprises and healthcare and insurance institutions are no longer optional, but constitute a mandatory component of early-stage business planning (Drummond et al., 2024; Kaló et al., 2023).

3.3.3 The HTA Barrier: Navigating the EU Joint Clinical Assessment

The implementation of the EU Health Technology Assessment Regulation (HTAR) and its corresponding Joint Clinical Assessment (JCA) represents a critical obstacle for market access and commercial viability in the European market. A fundamental challenge for an innovative pharmaceutical industry to overcome these difficulties, in navigating this

landscape is the methodological divergence identified between regulatory agencies, such as the European Medicines Agency (EMA), and HTA bodies.

While regulators frequently utilize accelerated approval pathways based on surrogate outcomes, such as clinical study progression in order to expedite patient access, in contrary HTA agencies typically require robust, longitudinal clinical outcomes, including overall survival and quality-adjusted life years (QALYs), to justify reimbursement (Eichler et al., 2016; Angelis et al., 2018). Consequently, contemporary pharmaceutical firms can no longer rely on isolated research and development strategies, but require "Early Dialogues" (or parallel scientific advice) with both regulators and HTA bodies during the Phase II/III trial design stage (Tafuri et al., 2014).

This proactive communication with regulation authorities is essential to align trial protocols with the specific active comparators and to the economic outcome that will be required by institutional payers for reimbursements. Ultimately, if the JCA concludes that a scientifically novel therapy provides no added therapeutic value compared to existing, off-patent standards of care, its commercialization across the European market is severely restricted (Julian et al., 2022).

3.4 Global Outlook to 2030: Supply-Demand-Financial Alignment

As the innovative biopharmaceutical industry moves within an unprecedented scientific and financial landscape, previous traditional metrics defining successful opportunity exploitation are being fundamentally re-evaluated, as at the current era a business plan heavily relying on regulatory approvals and subsequent negotiations with health insurance institutions for a favorable reimbursement rate, is no longer viable. Utilizing predictive models and market projections (e.g., IQVIA, 2025; Clarivate, 2026), it is evident that the defining "Drugs to Watch" in 2029 are those that can successfully navigate the "Sustainability Paradox".

This paradox encapsulates the core operational challenge of the modern era: providing cutting-edge, highly complex molecular innovations while simultaneously maintaining a manageable cost burden for global healthcare systems and ensuring physical product availability (Berti & Cunha, 2023).

To resolve this paradox, modern innovative business planning must overcome traditional isolation phenomena within corporate structure and deeply integrate supply chain logistics with financial forecasting and real-time patient demand (Anaplan, 2026; Cencora, 2026).

Overall, it is concluded that Managing these infrastructural limitations ("bottlenecks") is a core requirement of Ecosystem Management, as firms must ensure that the diagnostic and administrative infrastructure is as robust as the therapeutic process itself.

3.4.1 Sustainable Supply Chains and Agility in Manufacturing

Within the contemporary biopharmaceutical landscape, operating under isolated or rigidly linear manufacturing strategies constitutes a severe corporate drawback. "In view of the inherent vulnerabilities identified across global pharmaceutical supply chains, innovative firms are executing a strategic repositioning from current, 'just-in-time' inventory models, to 'just-in-case' organizational architectures specifically designed to ensure operational agility and structural robustness (Shih, 2020). To effectively operationalize this transition, strategic planners are increasingly adopting advanced Integrated Business Planning (IBP) frameworks capable of engineering sustainable, AI-driven supply networks (Anaplan, 2026).

These integrated frameworks deploy predictive algorithms, linking real-time epidemiological patient demand with upstream active pharmaceutical ingredient (API) sourcing and localized manufacturing batches (Anaplan, 2026). By achieving this level of systemic optimization, pharmaceutical enterprises can drastically mitigate inventory waste, optimize highly complex bioprocessing cycles, and structurally reduce the overall Cost of Goods Sold (COGS).

3.4.2 The GLP-1 Infrastructure Bottleneck: A Lesson in Physical Constraints

The absolute necessity of synchronized supply-demand-financial alignment could be comprehended by the case of the recent increase in commercial demand of GLP-1 receptor agonists (such as Wegovy and Zepbound) for the treatment of obesity (Müller et al., 2022).

This therapeutic class represents the defining commercial success of the mid-2020s (IQVIA, 2024).

Historically, the primary risk associated with the successful introduction of an innovative pharmaceutical compound, was mainly defined in terms of intellectual property protection against generic entry. For the GLP-1 class, however, the existential challenge was not the patent cliff, but rather physical supply demand compliance (Tucker, 2023). The initial business planning for these assets was initially focused on the clinical efficacy and regulatory validation of the innovative molecule and consequently the manufacturers vastly underestimated the global infrastructural capacity required to produce highly complex peptide formulations as the GLP-1 receptor agonists, including challenges in dosage form, as the autoinjector pens used during the drug administration (Ding et al., 2024). The resulting global shortages and subsequent revenue losses definitively demonstrate that a commercial "opportunity" cannot be fully exploited if the physical manufacturing, the delivery supply chain and logistics organization is not scaled concurrently with the market access strategy (ASHP, 2024; Shih & Pisano, 2024).

3.4.3 The Radioligand Bottleneck: Managing Decay and Just-in-Time Logistics

The absolute reliance of commercial exploitation upon physical supply chain capabilities is further exemplified by the emergence of targeted radioligand therapies (RLTs), such as lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for the treatment of advanced prostate cancer. Unlike traditional biologics or small molecules, which can be manufactured in large batches and launched through typical distribution channels, RLTs are fundamentally constrained by the physical half-life of their radioactive isotopes. In detail, Lutetium-177 isotope is characterized by a half-life of approximately 6.7 days, which indicates a highly rigid, ultra-short manufacturing and delivery window (Sgouros et al., 2020).

Consequently, the commercialization of Pluvicto exposed a severe global infrastructural deficit in specialized nuclear manufacturing facilities. Despite the demonstrated clinical efficacy and significant market demand, the manufacturer was obligated to temporarily halt new patient enrollments during its initial launch phase, as the existing global supply chain could not support the required continuous, "just-in-time" production schedules (Hagemann et al., 2023).

These logistical restrictions highlight that in the modern era of precision medicine, business planning must extend beyond successful clinical validation, as the economic viability of an innovative therapeutic product is entirely dependent on the firm's capacity to engineer and scale a highly specialized, time-sensitive logistical ecosystem before market launch (Ahmad & Kulkarni, 2024).

3.4.4 Predictive Portfolio Management: The "Multi-Niche" Architecture

Following the examination of preceding cases, it becomes evident that successful predictive portfolio management within the innovative pharmaceutical industry necessitates a structural transition away from monothematic drug products. Instead, contemporary strategies require the simultaneous targeting of multiple distinct patient populations and specific market segments (Jørgensen, 2011; Pharmaceutical Technology, 2024). As documented by Clarivate (2026), the traditional era of monolithic, mass-market pharmaceutical compounds is progressively being displaced by the systematic deployment of 'multi-niche' asset architectures. Under this new paradigm, opportunity exploitation relies heavily on rigorous portfolio diversification, rather than focusing exclusively on singular, highly capitalized mass-market launches (Gautam & Pan, 2016).

Consequently, strategic planners are increasingly directed to deploy a single, highly versatile biological mechanism across multiple specialized, rare, or genetically defined disease states simultaneously (Giarratana & Santaló, 2020). This fragmented, 'multi-niche' approach empowers firms to maximize financial sustainability by extracting value from diversified global healthcare budgets. Furthermore, it mathematically mitigates the downside risk associated with relying upon a single payer demographic or primary-care indication, while effectively easing supply-side production constraints by serving smaller, highly targeted patient cohorts (Pharmaceutical Technology, 2024).

3.5 ESG as a Market Access and Business Planning Pillar

Historically, the biopharmaceutical sector approached Environmental, Social, and Governance (ESG) criteria as secondary, non-financial attributes, assigning them to the periphery of traditional Corporate Social Responsibility (CSR) factors. Operating within this obsolete framework, biopharmaceutical firms treated ESG programs as isolated, defensive tactics aimed at safeguarding corporate reputation and managing stakeholder optics. As a result, these factors were utilized mostly as risk-mitigation tools instead of being structurally embedded into the organization's commercial planning structures and long-term value creation assets (Porter & Kramer, 2006).

However, in the current paradigm, a pharmaceutical business plan is considered fundamentally incomplete and economically unsustainable unless it systematically quantifies and mitigates the environmental and social extraversion associated with innovative therapeutics (Bocken et al., 2014). Hence, novel pharmaceutical industry sustainability has transitioned from a voluntary ethical framework into a austere obligations, directly influencing market access and redefining the overall value proposition of healthcare assets (Pharma Focus Europe, 2026). Consequently, the theoretical boundaries of commercial "opportunity exploitation" have been permanently extended, as now an innovative pharmaceutical asset is considered as commercially viable only if its exploitation strategy successfully satisfies the stringent ESG requirements established by regulatory authorities, institutional payers, and equity investors (Eccles, Ioannou, & Serafeim, 2014).

3.5.1 The Codification of ESG: Statutory Mandates and Market Access Barriers

The transition of ESG compliance from a corporate culture to a strict statutory requirement, is primarily mandated by international regulatory frameworks that legalize or reject non-compliant innovations. Within the European Union, the comprehensive revision of general pharmaceutical legislation has intensified the Environmental Risk Assessment (ERA) as a definitive regulatory prerequisite. Under this updated framework, the European Medicines Agency (EMA) retains explicit statutory authority to refuse marketing authorization if the

environmental risks associated with a therapeutic's lifecycle (from API synthesis to post-consumer disposal), are not adequately mitigated (European Commission, 2023).

3.5.2 The "Social" Pillar: Health Equity and Launch Mandates

The "Social" dimension of the Environmental, Social, and Governance (ESG) framework has systematically reconfigured pre-clinical developmental predictions, as in the current pharmaceutical industry environment, the regulatory bodies now strictly require demographic representation (Knepper & McLeod, 2018). Specifically, the U.S. Food and Drug Administration (FDA) has formalized the requirement for "Race and Ethnicity Diversity Plans" during the early stages of clinical development.

Under this requirement, regulators often reserve the authority to delay or deny New Drug Applications (NDAs) when clinical studies were performed on homogeneous ethnical populations that fail to represent true epidemiological distributions and differentiations (FDA, 2022). On the other hand, within the European Union, various legislative revisions have been introduced, requiring pharmaceutical manufacturers to ensure the equitable availability of innovative therapeutics across all Member States within highly compressed timeframes, actively addressing historical disparities in regional market access (European Commission, 2023; Main, Schäfer, & Kanavos, 2025).

For this purpose, contemporary strategic planners must proactively engineer sophisticated, tiered-pricing architectures designed to facilitate the equal access to innovative medication and to bridge the "Equity Gap." However, this market access strategy has to be executed within precise macroeconomic predictions in order to mitigate financial challenges triggered by International Reference Pricing (IRP) mechanisms routinely applied by higher-GDP jurisdictions (Fontrier, Gill, & Kanavos, 2019).

3.5.3 The "Environmental" Pillar: Circularity and Continuous Manufacturing

The environmental footprint associated with pharmaceutical production is currently being systematically monetized and penalized within the global drug industry marketplace. Institutional payers, as the UK's National Health Service (NHS), has now introduced the

application of a therapeutic's environmental impact factor into their formalized health technology procurement algorithms (National Health Service England, 2023; Tennison et al., 2021). For this purpose and in order to secure competitive formulary positioning, contemporary business planners have to proactively implement robust "Green Manufacturing" approaches, including substantial reductions (often exceeding 50%) in energy utilization, solvent waste, and overall water consumption (Burcham et al., 2018; Schaber et al., 2011).

Furthermore, for complex delivery mechanisms such as autoinjector devices, strategic planning must comprehensively account for the product's entire lifecycle. This necessitates the implementation of Digital Product Passports (DPPs) to establish end-to-end component traceability and ensure absolute compliance with the European Union's stringent circular economy and ecodesign regulations (Baker McKenzie, 2026; Heinrich & Lang, 2023).

3.5.4 Supply Chain Transparency as a Capital Expenditure (CapEx) Driver

Under the aforementioned Environmental, Social, and Governance (ESG) pillars approach, Governance has surpassed its traditional boundaries of internal corporate oversight towards functioning as a critical risk-mitigation factor within contemporary corporate finance. Accelerated by the regulatory requirements described in the European Union's Corporate Sustainability Due Diligence Directive (CS3D), biopharmaceutical enterprises are now held legally obligated to identify, prevent, and mitigate human rights violations and environmental degradation across their entire global value chains.

To resolve the inherent information asymmetry between manufacturers, regulators, and investors, firms are increasingly utilizing distributed ledger technologies (DLTs), specifically blockchain architectures, to establish absolute, without exceptions supply chain transparency (Centobelli et al., 2022). These technologies provide verifiable evidence that critical parameters, ranging from specialized lipid nanoparticles and cell culture media to rare-earth components utilized in medical devices, are utilized in strict compliance to ethical and ecological standards (Saberi et al., 2019).

From a corporate finance perspective, this verified governance has evolved into a dominant prerequisite for Capital Expenditure (CapEx) allocation. Institutional investors and global

venture capital consortia now systematically thoroughly examine biopharmaceutical entities in terms of transparent procurement operations and verified supplier networks (Amel-Zadeh & Serafeim, 2018).

Consequently, an organization that fails to substantiate robust governance metrics will face prohibitive increases in its weighted average cost of capital (WACC) or outright exclusion from institutional financing pools (Friede, Busch, & Bassen, 2015).

Table 3.1: Strategic Mechanisms for Navigating Late-Stage Commercial Barriers

Commercial Barrier / Threat	**Strategic Mitigation Mechanism**	**Pharmaceutical Paradigm (Case)**	**Commercial & Operational Outcome**
Patent Cliff & Generic Market Entry	**Multi-Modal Lifecycle Management:** Systematic "Strategic Switches" and continuous indication expansion.	**Merck** (*Keytruda*)	Proactively migrates the patient base to next-generation delivery mechanisms (e.g., subcutaneous formulations), effectively decoupling the asset's clinical value from its original statutory expiration date.
Formulation Replicability & Automatic Substitution	**Servitization & Formulation Complexity:** Engineering Long-Acting Injectables (LAIs) to transform a product into a clinic-administered service.	**Janssen** (*Invega*) & **ViiV** (*Cabenuva*)	Neutralizes the threat of pharmacy-level generic substitution by utilizing extreme formulation complexity (e.g., nanocrystal suspensions), rendering reverse-engineering technically prohibitive.
"Ceiling of Affordability" for High-Cost ATMPs	**Value-Linkage:** Implementing Outcome-Based Risk-	**Novartis** (*Zolgensma*)	Bridges informational asymmetry between manufacturer and payer; high

	Sharing Agreements (OBRSAs) and annuity-based payment models.		capitalized costs are distributed over time and reimbursement is strictly tied to verified real-world clinical milestones.
The "Sustainability Paradox" & Physical Constraints	**Supply-Demand Alignment:** Transitioning to "just-in-case" architectures and synchronized logistics for highly complex delivery systems.	**Novo Nordisk** (*Wegovy*) & **Novartis** (*Pluvicto*)	Mitigates catastrophic revenue losses caused by global infrastructure bottlenecks (e.g., autoinjector scaling or radioactive isotope decay) by scaling the physical supply network concurrently with market access.
Mass-Market Boom-and-Bust Cycles	**Predictive Portfolio Management:** Shifting away from monolithic blockbusters toward portfolio diversification.	**Industry Trend** (*Multi-Niche Architecture*)	Maximizes financial sustainability by deploying a single biological mechanism across multiple rare or distinct indications, effectively managing supply-side constraints and spreading payer risk.
Statutory ESG Mandates & Capital Restriction	**Value-Chain Transparency:** Embedding "Green Manufacturing," demographic equity plans, and immutable digital ledgers.	**FDA Diversity Plans / EU CS3D Mandates**	Transforms ESG from a PR exercise into a core CapEx driver. Firms secure institutional funding and market access by proving ethical sourcing via blockchain and reducing environmental footprints via Continuous Manufacturing (CM).

4. Conclusion: The 2030 Horizon for Innovative Drug Products

As been meticulously explained on the previous chapters, biopharmaceutical industry currently stands at a critical inflection point, driven by the unprecedented convergence of different critical contributing factors, as the biological complexity of the innovative pharmaceutical compounds, the advances in computational engineering and the of integration of artificial intelligence and machine learning, the constraints in a contemporary pharmacoeconomic environment and the increasing requirements of regulatorily authorities for innovative pharmaceutical products launch. The research presented in this dissertation demonstrates that the foundational mechanisms of creating and capturing value proposition in the healthcare sector have fundamentally and permanently shifted (Amit & Zott, 2012; Teece, 2010).

As we look toward the 2030 horizon, it is evident that the traditional examples of drug discovery and commercialization are no longer viable (Scannell et al., 2012). To overcome this structural productivity crisis, pharmaceutical planners must transition from random and often coincidental drug discovery to systematic, AI-driven pathway engineering. This approach heavily relies on "computational capital" to de-risk highly capitalized assets before physical clinical trials are initiated (Iansiti & Lakhani, 2020).

Furthermore, the previous era of standalone therapeutic compensation and insurance policies are now rapidly superseded by integrated healthcare ecosystems, where market access and reimbursement are strictly contingent upon proven real-world value-linkage and absolute compliance with emergent Environmental, Social, and Governance (ESG) mandates (Kaló et al., 2023; Pharma Focus Europe, 2026). Hence, future perspectives are relying on the formation of novel "Tech-Bio" hybrid organizations capable of dynamically organizing and evaluating these multidimensional variables to ensure sustainable, outcome-based innovation.

4.1 Synthesis of Findings: The Death of the "Random Walk"

The traditional "random walk" of drug discovery, historically characterized by the stochastic, incidental screening of vast chemical libraries is officially obsolete (Swinney & Anthony, 2011). This study has systematically demonstrated that Opportunity Identification within the modern biopharmaceutical landscape has transitioned from a passive discovery paradigm to a disciplined, rigorous process of Strategic Pathway Engineering (Alvarez & Barney, 2007; Teece, 2007).

The most profound shift is conceptual, as the intrinsic novelty of the chemical or biological entity is no longer the sole determinant of commercial viability. Instead, the molecule is only one factor that operates within a highly complex pharmaceutical industry environment, consisting of Regulatory Intelligence, Real-World Evidence (RWE), and meticulously designed Integrated Evidence Plans (IEPs) (Olson & Capkun, 2024).

In the contemporary era, firms that fail to prospectively engineer appropriate clinical data and value dossiers, structured to clearly demonstrate the cost-effectiveness and medical necessity of a new drug, are no longer considered innovative (DiMasi et al., 2024). In contrary, they are characterized as strategically inefficient and fundamentally underequipped, so as to survive the compounding pharmacoeconomic pressures, affordability ceilings, and value-based reimbursement models of the modern healthcare sector (Kaló et al., 2023).

4.2 The New Value Equation: Tech-Bio Hybrids and ESG Mandates

The research into Strategic Exploitation (Chapter 2) reveals that the widely cited $2.6 billion capitalized R&D cost-to-market (DiMasi, Grabowski, & Hansen, 2016) is being aggressively challenged. However, this economic challenge is not being led by advancements in traditional chemistry or phenotypic screening, but by the deliberate deployment of superior Computational Capital (Iansiti & Lakhani, 2020). Strategic alliances have permanently shifted away from conventional approaches as the licensing a single late-stage molecule—towards deep "capability-integration" involving hyperscale cloud providers and AI-native startups (IntuitionLabs, 2026).

By 2030, the most successful pharmaceutical firms will have to operate as "Tech-Bio Hybrids" as mentioned above, taking advantage of agentic AI systems and massive FAIR-compliant data alliances to entirely eliminate the "Bio-Digital Gap" (Jayatunga et al., 2022; Wilkinson et al., 2016). Furthermore, the integration of Environmental, Social, and Governance (ESG) criteria (Chapter 3) has demonstrated that the definition of an "Innovation" process in the pharmaceutical sector has been legally and economically repositioned.

Under the strict current authorities frameworks, such as the revised EU pharmaceutical legislation, a drug that is clinically superior but environmentally or socially inappropriate, will inevitably face a severe "Value Penalty" or complete rejection from global payers and Health Technology Assessment (HTA) bodies (European Commission, 2023; Pharma Focus Europe, 2026). Consequently, sustainability and health equity are no longer relegated to corporate public relations exercises; they are absolute, statutory prerequisites for securing Market Access and ensuring the holistic exploitation of a commercial opportunity (Avalere Health, 2026; Baker McKenzie, 2026).

4.3 Future Projections (2026–2030)

Based on the synthesis of current strategic literature, three major macro-shifts will define pharmaceutical business planning over the next five years:

4.3.1 The Rise of the "N-of-1" Blockbuster and Modular Manufacturing

The traditional mass-market biopharmaceutical strategy is progressively being inverted in favor of ultra-personalized therapeutic interventions. The modern pharmaceutical business plan is increasingly designed for a population of one, establishing the paradigm of the single, patient-specific pharmaceutical products ("N-of-1" personalized drugs model). Scientifically, this operational shift is validated by historic breakthroughs in customized, patient-specific *in vivo* gene editing.

Case Paradigm: *In Vivo* Base Editing for Rare Metabolic Deficiencies

Instead of relying on early-generation *ex vivo* cellular modifications, the 2030 commercial trends in contemporary molecular biology applications in pharmaceutical industry are defined by *in vivo* precision genomic manipulation. A representative example of this shift could be found in the clinical deployment of customized adenine base-editing therapies delivered via target-specific lipid nanoparticles (LNPs). In clinical models, such as the treatment of carbamoyl phosphate synthetase 1 (CPS1) deficiency in infants, this approach enables the direct correction of single-nucleotide polymorphisms in hepatocytes without inducing double-strand DNA breaks (Musunuru et al., 2025; Gropman, & Komor, 2025) .

From a business planning perspective, this transforms the therapeutic process from the previous approach that includes application of a static chemical entity into the modern approach of a programmable platform therapeutic process.

To commercialize these "N-of-1" interventions without triggering subsequent pharmacoeconomic concerns, business planners are transitioning from the classic approach where gigantic drug manufacturing facilities dedicated to a single commercially successful drug product to automated, micro-factories capable of rapidly coding mRNA sequences and formulation vectors on-demand.

Supported by real-time regulatory assistance and *in silico* Digital Twin simulations designed to predict and optimize the manufacturing process, this integrated infrastructure effectively transforms highly customized cell and gene therapies (CGTs) from academic research areas into feasible, sustainable and commercially scalable business models.

The rapid engineering and successful *in vivo* administration of this targeted therapy demonstrates the absolute clinical feasibility of individualized genetic medicine.

Case Paradigm: *In Vivo* Base Editing for Systemic Cardiovascular and Amyloid Target Disruption

As the business model for *in vivo* programmable therapeutics scales, strategic planners are expanding platform utility from ultra-rare point mutations to broader, systemic chronic diseases via targeted gene knock-down mechanisms (Musunuru, 2023). A contemporary manifestation of this horizontal scaling approach is the *in vivo* gene-editing therapies during clinical deployment, as in the case of the permanent disruption of disease-causative genes

in the liver (Gillmore et al., 2021). By packing a Cas9 or base-editor mRNA and a highly specific single-guide RNA (sgRNA) into liver-directed lipid nanoparticles, developers have successfully executed precise gene knockouts via non-homologous end joining or targeted single-nucleotide transitions (Qiu et al., 2021).

Case Paradigm: Casgevy and the Commercialization of CRISPR

The operational reality of the "N-of-1" business model is best exemplified by the recent regulatory approvals of Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta-thalassemia. As been the first FDA and EMA-approved therapy utilizing CRISPR/Cas9 genome editing, the commercial launch of Casgevy does not utilize a traditional supply chain, rather than requires an entirely dedicated, *ex vivo* manufacturing loop (Frangoul et al., 2021; Figure 5). The patient's own hematopoietic stem cells must be extracted, transported to a specialized manufacturing facility, genetically edited, and then re-infused following myeloablative conditioning. The strategic exploitation of Casgevy proves that future business planning must shift from scaling molecular production to scaling complex, decentralized clinical logistics and establishing certified "Treatment Centers" as proprietary commercial exclusivities (Jørgensen, Hanna, & Kefalas, 2024; Lummerstorfer & Musunuru, (2026).

Figure 5: The "N-of-1" Decentralized Clinical Logistics Loop of CRISPR/Cas9 genome editing therapy



4.3.2 The End of the Traditional "Patent Cliff" via System-Level Complexity

Through "Strategic Switches" and sophisticated "Multi-Modal Lifecycle Management" mentioned before, pharmaceutical firms are systematically transitioned from typical static product launches towards continuous innovation loops (Song & Lee, 2016). Subsequently, the generated intellectual property (IP) will be protected not only as a novel chemical formula, but also by the irreplicable complexity of the combined digital and biological delivery systems required to administer the therapy safely and effectively (Teece, 2010), operating under a complete healthcare services ecosystem (Baines et al., 2017).

By applying these infrastructural limitations, the typical perception of the single-factor "patent cliff" , where a rapid decline in revenue occurs when the company's exclusive rights to this factor expires, is now considered obsolete. Thus the current tendency in intellectual property protection by the pharmaceutical companies, is to secure a long-term commercial viability of a novel pharmaceutical product through systemic complexity instead of safeguarding its chemical exclusivity (Song & Lee, 2016).

Case Paradigm: Leqembi and the "Infrastructural Moat"

The concept of system-level complexity replacing the traditional patent cliff is clearly demonstrated by the commercialization of **Leqembi (lecanemab)** by Eisai and Biogen for Alzheimer's disease. In detail, the business plan is the implementation of an Alzheimer's disease-modifying therapy, entirely dependent on a surrounding diagnostic ecosystem (van Dyck et al., 2023). Exploitation requires patients to undergo parallel diagnostic examinations, as the baseline positron emission tomography (PET) scans, the cerebrospinal fluid (CSF) testing and the magnetic resonance imaging (MRI), in order to to confirm amyloid pathology and to monitor for potential Amyloid-Related Imaging Abnormalities (ARIA). Consequently, the intellectual and commercial value is not merely the pharmaceutical drug administration, but the firm's ability to integrate therapeutic delivery with advanced neuro-radiological infrastructure. Generic or biosimilar entrants cannot easily disrupt this market upon patent expiration because they cannot replicate the required clinical workflow and specialized physician training networks (Cummings et al., 2023).

4.3.3 The Payer-as-Partner: Outcome-Based Risk-Sharing Agreements (OBRSAs)

Historically, the dynamic between biopharmaceutical manufacturers and institutional payers, as the global healthcare or insurance organizations, has been fundamentally antagonistic, characterized by open negotiations. However, the commercialization of high-cost, single-dose advanced therapies, has rendered this model obsolete, as traditional healthcare budgets cannot readily absorb the revised increased costs without guaranteed, long-term clinical durability (Drummond et al., 2024).

Driven by this absolute economic necessity, the commercial paradigm is structurally shifting toward Outcome-Based Risk-Sharing Agreements (OBRSAs; Carlson et al., 2017; Garrison et al., 2015), as also been discussed in previous chapter 3. Under this framework, the relevant value proposition and opportunity exploitation evolves from simple transactional events into a shared, data-driven longitudinal partnership (Kaló et al., 2023).

Subsequently, contemporary corporate financial success is fundamentally aligned with public health outcomes, where the manufacturing firm gains a sustainable profitability only when the patients achieve verified, measurable health milestones validated through the systematic, post-market generation of Real-World Evidence (RWE) (Garrison et al., 2015; Kaló et al., 2023).

Case Paradigm: Hemgenix and the $3.5 Million Price-to-Value Limit

The absolute necessity for the application of Outcome-Based Risk-Sharing Agreements (OBRSAs) is illustrated in the case of the commercial launch of Hemgenix (etranacogene dezaparvovec -drlb) pharmaceutical compound. Manufactured by Genezen MA, Inc. and distributed by CSL Behring LLC biotechnological company for severe and moderately severe Hemophilia B treatment, Hemgenix consists of the first ever FDA-approved gene therapy launched with a list price of $3.5 million per dose, making it the most expensive single therapeutic in history at the time of its approval (FDA, 2022). However, at this price, the pharmaceutical compound became prohibitive for the typical fee-for-service pharmacoeconomic models. Thus, in order to achieve market access, CSL Behring's

business planning required the implementation of value-based warranties with commercial insurers, where the manufacturer reimburses the payer if the patient requires prophylactic factor IX infusions within a specified post-treatment window (Drummond et al., 2024). Hemgenix serves as the definitive precedent that for curative, high-cost advanced therapies, the product is inseparable from its financial risk-sharing vehicle.

Case Paradigm: Roctavian and Real-World Value-Based Contracts

A similar to previously described case of OBRS agreement and Hemgenix (developed for Hemophilia B therapy), could also be found in the commercialization of a similar compound valoctocogene roxaparvovec (Roctavian). Developed by BioMarin Pharmaceutical, consists of a one-time adeno-associated virus gene therapy approved for the treatment of a different hemophylic disorder, the severe hemophilia A.

In this case, the pharmaceutical product has entered the United States market with a list price of approximately $2.9 million, where as the case of Hemgenix, the therapy presented immediate serious affordability concerns (Zemplenyi et al., 2023).

While traditional cost-effectiveness predictions assumed that that the significant upfront cost would be mitigated by eliminating the need for conventional lifelong treatments and healthcare provisions, this hypothesis was heavily relied on assumptions rather than proven, long-term clinical data (Alshehri et al., 2024). Recent pharmacoeconomic modeling utilizing real-world analysis demonstrated a substantial financial uncertainty for treatment administration, where projections have demonstrated that a time period of at average 8 years, will be required so as the initial investment to be returned to the health insurance institutions (Zemplenyi et al., 2023).

To overcome this barrier and facilitate patient access, a similar to Hemgenix approach was followed, where value-based contracts (VBCs) and outcome-based warranties have been increasingly proposed and implemented. Under these arrangements, the financial risk is systematically shared between the payer and the manufacturer; reimbursements or rebates are tied directly to the therapy's real-world clinical performance over time, ensuring that the healthcare system is financially protected if the patient fails to maintain the targeted clinical outcomes (Alshehri et al., 2024; Zemplenyi et al., 2023).

Table 4.1: The 2030 Horizon—Paradigm Shifts in Innovative Biopharmaceutical Business Planning

Strategic Projection / Shift	**Foundational Mechanism**	**Pharmaceutical Paradigm (Case)**	**Commercial & Operational Implication**
The Death of the "Random Walk" & Rise of Tech-Bio	**Strategic Pathway Engineering & Computational Capital:** Replacing stochastic, trial-and-error discovery with AI-driven predictive modeling and FAIR-compliant data alliances.	**Industry Trend** (*Tech-Bio Hybrids*)	Eliminates the "Bio-Digital Gap"; the chemical molecule becomes a mere "passenger" while the "vehicle" (Integrated Evidence Plans, RWE, and regulatory intelligence) dictates commercial survival.
"N-of-1" Blockbusters & Modular Manufacturing	**Individualized Genetic Medicine:** Transitioning from mass-market chemical production to programmable, patient-specific *in vivo* and *ex vivo* genomic manipulation.	**Vertex & CRISPR Therapeutics** (*Casgevy*)	Business planning shifts from scaling global molecular production to scaling highly complex, decentralized clinical logistics, micro-factories, and proprietary "Certified Treatment Centers".
System-Level Complexity vs. Traditional Patent Cliffs	**The Infrastructural Moat:** Securing intellectual property and market share through irreplicable, integrated diagnostic	**Eisai & Biogen** (*Leqembi*)	Replaces single-factor chemical patents with systemic complexity. Generic entrants are blocked not only by patents but by the inability to replicate

	and delivery ecosystems.		mandatory diagnostic workflows (e.g., required PET/MRI monitoring).
The Payer-as-Partner via OBRSAs	**Longitudinal Value-Based Contracts (VBCs):** Transitioning from isolated transactional pricing to data-driven, shared-risk financial vehicles and clinical warranties.	**CSL Behring** (*Hemgenix*) & **BioMarin** (*Roctavian*)	Mitigates the "affordability ceiling" for multi-million-dollar ATMPs. The therapeutic product is now commercially inseparable from its risk-sharing vehicle, tying reimbursement strictly to sustained Real-World Evidence (RWE) milestones.
ESG as an Absolute Market Access Prerequisite	**Statutory Sustainability & Equity Mandates:** Enforcing Environmental, Social, and Governance criteria as non-negotiable regulatory gateways.	**FDA Diversity Plans & EU Launch Obligations**	Transforms ESG from a peripheral public relations exercise into a fundamental driver of institutional CapEx financing, regulatory approval (e.g., Environmental Risk Assessments), and international market access.

5. Chapter 5: Final Contribution of the Study

The preceding chapters of this dissertation have systematically mapped the profound evolution of opportunity identification, strategic exploitation, and lifecycle management within the innovative biopharmaceutical industry. By critically examining the transition from serendipitous, mass-market drug discovery to the highly engineered, AI-driven architectures of the contemporary era, this study has deconstructed the multidimensional challenges that modern pharmaceutical planners must navigate.

5.1 Discussion of Key Findings and Sectoral Analysis

This sectoral analysis addressed how modern firms identify and validate commercial opportunities under the constraints of Eroom's Law. The findings reveal that opportunity identification has irreversibly transitioned from passive phenotypic discovery to the systematic application of "Entrepreneurial Alertness". As has been extensively discussed on the previous chapters, innovative pharmaceutical firms actively construct opportunities by scanning digital health ecosystems, associating clinical abnormalities or even failed studies with latent markets, and leveraging expedited regulatory pathways, under accelerated or fast track approval of the innovative products.

Furthermore, regarding strategic exploitation, the analysis demonstrates that value creation has fundamentally shifted from primarily relying on proprietary physical and intellectual capital to a contemporary "Computational Capital" accumulation. As has been explained, in order to overcome systems biology complexities, pharmaceutical enterprises are transforming into "Tech-Bio" hybrids, utilizing Agentic AI, *in silico* clinical trial virtualization, and open innovation alliances to de-risk highly capitalized assets before physical clinical trials are initiated.

Finally, the findings regarding late-stage commercial barriers indicate that traditional "evergreening" tactics to artificially extend the commercial exclusivity of a pharmaceutical product beyond the standard expiration date, are obsolete. To navigate post-exclusivity patent cliffs, affordability ceilings, and the "Sustainability Paradox," firms must deploy

Multi-Modal Lifecycle Management, secure complex infrastructural moats and competitive advantages, and integrate Outcome-Based Risk-Sharing Agreements (OBRSAs) even at the early conceive of the business models.

In conclusion, this dissertation has highlighted that innovative business planning within the pharmaceutical industry has evolved from a linear, financially-driven exercise into an extensively complex, multidimensional scientific and fiscal ecosystem. The primary thesis of this research is confirmed under the conclusion that the intrinsic novelty of a chemical or biological entity no longer guarantees commercial success. On the contrary, value creation and value proposition demand the presence of three core competencies: i. the entrepreneurial alertness to identify latent regulatory and clinical gaps, ii. the technological capability to construct AI-driven exploitation platforms, and iii. the ethical foresight to ensure fundamental sustainability and equitable access. In the contemporary biopharmaceutical environment, the active ingredient is merely the foundational prerequisite; the true commercial opportunity lies in the speed, precision, and systemic integrity of the strategic pathway engineered to deliver that innovation to the patient.

5.2 Theoretical Contributions to Innovation Management

This dissertation contributes to the Academic understanding of Innovation Management and Entrepreneurship by extending traditional theoretical frameworks into the highly regulated, Knightian uncertainty of the biopharmaceutical sector.

In detail, the dissertation attempts to synthesize three distinct, but interconnected, literature streams:

i. Entrepreneurial Discovery and Creation Theory: By bridging the Kirznerian model with Alvarez & Barney's creation theory, this study addresses the gap regarding how high-uncertainty industries operationalize opportunity identification.

ii. Dynamic Capabilities (Teece): By mapping these onto the pharmaceutical lifecycle, we address the gap in understanding how 'sensing, seizing, and transforming' are operationalized in a hyper-regulated sector.

iii. Open Innovation (Chesbrough): This study addresses the gap in understanding how 'Computational Capital' functions as a mechanism for Open Innovation ecosystems.

Apart from the aforementioned synthesis of Innovation Management literature streams, the dissertation attempts to address various identified research gaps, which have not to this date confronted under a holistic way:

i. Addressed Gaps: The literature previously treated these streams in isolation; this study bridges them by demonstrating that entrepreneurial alertness is not just an individual cognitive trait, but a systemic organizational capability.

ii. Remaining Gaps for Future Research: Despite this synthesis, a gap remains regarding the quantitative measurement of these dynamic capabilities in pre-revenue 'Tech-Bio' startups. Furthermore, the role of algorithmic governance as a perquisite for a successful for market entrance rather than a post-development compliance necessity, remains an emerging area requiring to be meticulously studied in the future.

5.3 Practical Implications for Biopharmaceutical Management

For industry managers, strategic planners, and policymakers, this sectoral analysis offers actionable frameworks for real-world application. Managers can utilize the identified Integrated Business Planning (IBP) and "Fail-Fast" financial gating strategies previously explained, enhanced by "Digital Twins" approach, so as to rationalize R&D portfolios and minimize underperforming activities, unnecessary expenditures and late-stage clinical attrition.

For policymakers and Health Technology Assessment (HTA) bodies, the findings underscore the necessity of adopting Outcome-Based Risk-Sharing Agreements (OBRSAs) to balance the commercial viability of high-cost Advanced Therapy Medicinal Products (ATMPs) with the affordability ceilings of public healthcare systems.

Furthermore, the study highlights how startups and biopharma leaders must prospectively integrate Environmental, Social, and Governance (ESG) requirements, such as continuous green manufacturing and demographic trial diversity, not as peripheral Corporate Social Responsibility (CSR) activities, but as strict statutory prerequisites for securing capital expenditure (CapEx) and international market access.

5.4 Limitations of the Research

A primary limitation of this study is its methodological design as a secondary-research, literature-based sectoral analysis. While this approach allowed for a broad, comparative synthesis of macro-economic trends and multiple corporate case paradigms, it inherently lacks the horizontal, proprietary financial metrics and internal strategic decision-making data that a primary data collection would provide.

The reliance on publicly available secondary data, regulatory filings, and existing academic literature means the analysis is subject to external reporting limitations and potential publication bias. Furthermore, the rapid advances of technological sector, especially in generative AI and digital therapeutics implies that some of the computational frameworks and regulatory policies (such as the EU AI Act) discussed in this analysis are highly dynamic and may evolve beyond the currently described capacities. Finally, as noted by Scannell and Bosley (2016), literature-based syntheses of pharmaceutical R&D productivity can sometimes be constrained by the lack of reproducibility in its original research findings, which remains a significant challenge in this specific Academic area.

5.5 The Unified Conceptual Framework for Pharmaceutical Business Planning

To provide a cohesive overview of the dissertation's findings, Figure 6 presents the Integrated Pharmaceutical Business Planning Model. This provisional meta-framework visualizes the interconnectedness of the three core competencies identified in this research, demonstrating how they function as a unified system to transform a basic molecular compound into a sustainable commercial asset.

Figure 6: The Integrated Pharmaceutical Business Planning Model



In detail, in Figure 6 is mapped the operational progression of how **Entrepreneurial Alertness** senses commercial opportunities, how **Computational Capital** (Agentic AI and *in silico* ecosystems) exploits them within the clinical development framework, and how **Value-Linkage (OBRSAs) and ESG metrics** preserve them under strict market-access pressure that may occur. By explicitly framing this as a model inspired by Teece's Dynamic Capabilities, it is clearly illustrated how future researchers can empirically test or expand through the primary data methodologies currently provided, providing the theoretical background to innovation management theory.

5.6 Recommendations for Future Research

Future research should build upon this literature-based foundation by incorporating primary data collection methodologies. Conducting in-depth qualitative interviews with biopharmaceutical R&D executives, regulatory affairs principals, and HTA policymakers could provide critical empirical validation of the theoretical frameworks proposed herein.

Additionally, future studies could execute cross-sectoral comparative analyses, for example contrasting the AI-driven innovation models in biopharmaceuticals with those in relevant sectors, as the medical devices or even irrelevant but closely related, as the high-performance computing (HPC) or even the semiconductor industries (Moore's Law versus Eroom's Law). Another vital sector for future exploration is quantitative research measuring the long-term economic impact of the EU Artificial Intelligence Act on the R&D productivity and investment valuations of European "Tech-Bio" startups, specifically regarding the compliance costs of algorithmic governance.

References

Adner, R. (2006). Match your innovation strategy to your innovation ecosystem. *Harvard Business Review*, *84*(4), 98–107.

Ahmad, A., & Kulkarni, S. (2024). Overcoming supply chain bottlenecks in advanced therapy medicinal products: The case of radiopharmaceuticals. *Journal of Pharmaceutical Policy and Practice*, *17*(1), 45–58.

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., Mui, B. L., Semple, S. C., Chen, D., & Cullis, P. R. (2019). The Onpattro story and the clinical translation of nanomedicines. *Nature Nanotechnology*, *14*(12), 1084–1087. https://doi.org/10.1038/s41565-019-0591-y

Alshehri, A., Dougherty, J. A., Beckman, L., & Svensson, M. (2024). A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B. *Journal of Managed Care & Specialty Pharmacy*, *30*(10), 1178–1188. https://doi.org/10.18553/jmcp.2024.30.10.1178

Alvarez, S. A., & Barney, J. B. (2007). Discovery and creation: Alternative epistemologies and entrepreneurial action. *Strategic Entrepreneurship Journal*, *1*(1-2), 11–26.

American Society of Health-System Pharmacists. (2024). *National drug shortages database: GLP-1 receptor agonists*. ASHP Pharmacoeconomic Tracking.

Amit, R., & Zott, C. (2012). Creating value through business model innovation. *MIT Sloan Management Review*, *53*(3), 41–49.

Anaplan. (2026a). *IBP for pharma: Planning with strategic intelligence*. Anaplan & Intuition Labs Research.

Anaplan. (2026b). *Integrated business planning for life sciences: Supply chain and commercial alignment*. Anaplan & Intuition Labs.

Ardichvili, A., Cardozo, R., & Ray, S. (2003). A theory of entrepreneurial opportunity identification and development. *Journal of Business Venturing*, *18*(1), 105–123.

Ardigen. (2025). *Platform-as-a-partner: The future of AI-enabled drug discovery alliances*.

Arkes, H. R., & Blumer, C. (1985). The psychology of sunk cost. *Organizational Behavior and Human Decision Processes*, *35*(1), 124–140.

AstraZeneca. (2025). *Strategic AI alliances in small-molecule drug discovery: The CSPC Pharmaceutical partnership*.

Atomwise. (2025). *Virtual medicinal chemistry: Using deep convolutional neural networks to predict molecular binding*. Atomwise Research Publications.

Avalere Health. (2026). *Navigating affordability criteria in the revised EU pharmaceutical legislation*.

Baines, T., Bigdeli, A. Z., Bustinza, O. F., Shi, V. G., Baldwin, J., & Ridgway, K. (2017). Servitization: Revisiting the state-of-the-art and research priorities. *International Journal of Operations & Production Management*, *37*(2), 256–278.

Baker McKenzie. (2026). *The circular economy in life sciences: Digital product passports and ESG compliance*.

Bancel, S. (2021). *Moderna's operating system*. Moderna, Inc. Corporate Publications.

Barabási, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. *Nature Reviews Genetics*, *12*(1), 56–68.

Barney, J. (1991). Firm resources and sustained competitive advantage. *Journal of Management*, *17*(1), 99–120. https://doi.org/10.1177/014920639101700108

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M., ... & ILLUMINATE Investigators. (2007). Effects of torcetrapib in patients at high risk for coronary events. *The New England Journal of Medicine*, *357*(21), 2109–2122.

Berger, A. (1998). The rise and fall of Viagra. *BMJ*, *317*, 824. https://doi.org/10.1136/bmj.317.7161.824

Berti, M., & Cunha, M. P. (2023). Paradox, sustainability, and the business enterprise. *Society and Business Review*.

BioAgilytix. (2026). *Enabling a breakthrough in gene therapy: A case study in analytical support for CRISPR-based innovation*.

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of

eating, food preference and body weight in subjects with obesity. *Diabetes, Obesity and Metabolism*, *19*(9), 1242–1251.

Bocken, N. M. P., Short, S. W., Rana, P., & Evans, S. (2014). A literature and practice review to develop sustainable business model archetypes. *Journal of Cleaner Production*, *65*, 42–56.

Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2023). Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. *Expert Opinion on Drug Discovery*, *19*(1), 33–42. https://doi.org/10.1080/17460441.2023.2273839

Boston Consulting Group. (2025). *Breakthroughs at scale: The AI revolution in biopharma R&D*.

Bujar, M., McAuslane, N., Salek, S., & Walker, S. (2019). Review of the EMA PRIME scheme: A catalyst for innovation or simply an expedited pathway? *Frontiers in Pharmacology*, *10*, 876.

Burcham, C. L., Florence, A. J., & Johnson, M. D. (2018). Continuous manufacturing in pharmaceutical process development and manufacturing. *Annual Review of Chemical and Biomolecular Engineering*, *9*, 253–281.

Capgemini. (2025). *From task-AI to agentic ecosystems: ROI scaling in pharmaceutical clinical operations*.

Carlson, J. J., Sullivan, S. D., Garrison, L. P., Neumann, P. J., & Veenstra, D. L. (2017). Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement agreements between healthcare payers and manufacturers. *Health Policy*, *121*(8), 856–863.

Carmine, S., & De Marchi, V. (2023). Reviewing paradox theory in corporate sustainability toward a systems perspective. *Journal of Business Ethics*, *184*(1), 139–158.

Cencora. (2026). *Demand planning in an evolving pharmaceutical supply chain*. Cencora Human Health Insights.

Chen, B., Schneider, L. C., Röver, C., Comets, E., Elze, M. C., Hooker, A., IntHout, J., Jannot, A.-S., Julkowska, D., Mimouni, Y., Savelieva, M., Stallard, N., Ursino, M.,

Vandemeulebroecke, M., Weber, S., Posch, M., Zohar, S., & Friede, T. (2025). In silico clinical trials in drug development: A systematic review. *arXiv*. https://doi.org/10.48550/arxiv.2503.08746

Cheng, B., Wang, Y., Hong, Y., Zhou, Y., Peng, X., Chen, J., & Zeng, C. (2026). Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1. *PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC12905989/

Chesbrough, H. W. (2003). *Open innovation: The new imperative for creating and profiting from technology*. Harvard Business School Press.

Chesbrough, H., & Rosenbloom, R. S. (2002). The role of the business model in capturing value from innovation: Evidence from Xerox Corporation's technology spin-off companies. *Industrial and Corporate Change*, *11*(3), 529–555.

Clarivate. (2026). *Drugs to watch 2026: Predictive portfolio management and the multi-niche future*.

Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. *Administrative Science Quarterly*, *35*(1), 128–152.

Coherent Solutions. (2026). *TrialGPT and the optimization of EHR-based patient recruitment*.

Cooper, R. G. (2011). *Winning at new products: Creating value through innovation* (4th ed.). Basic Books.

Cortés-Ríos, J. (2025). A step-by-step workflow for performing in silico clinical trials with nonlinear mixed effects models. *CPT: Pharmacometrics & Systems Pharmacology*.

Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, *9*(2), e12385.

Danzon, P. M., & Furukawa, M. F. (2011). Prices and availability of pharmaceuticals: Evidence from nine countries. *Health Affairs*, *30*(9), 1636–1644.

Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2014). New FDA breakthrough-drug category—implications for patients. *The New England Journal of Medicine*, *370*(13), 1252–1258.

Davies, J., Sen, S., & Cox, A. (2012). Orphan designation in Europe: Is it a commercial opportunity? *British Journal of Clinical Pharmacology*, *74*(3), 540–541.

Deloitte. (2025). *The innovation-cost paradox: Reversing the decline in returns from pharma R&D*.

Detela, G., & Lodge, A. (2019). EU regulatory pathways for ATMPs: Standard, accelerated and adaptive pathways to marketing authorisation. *Molecular Therapy - Methods & Clinical Development*, *13*, 205–232. https://doi.org/10.1016/j.omtm.2019.01.010

Dilliard, S. A., & Siegwart, D. J. (2023). Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. *Nature Reviews Materials*, *8*(5), 282–300. https://doi.org/10.1038/s41578-022-00529-7

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics*, *47*, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012

DiMasi, J. A., Olson, M., Smith, Z., Getz, K. A., & Capkun, G. (2024). Assessing the value of integrated evidence approaches in drug development. *Springer Science and Business Media LLC*. https://doi.org/10.21203/rs.3.rs-4321838/v1

Ding, Y., et al. (2024). Manufacturing and supply chain challenges of peptide-based therapeutics and autoinjector delivery systems. *Journal of Pharmaceutical Innovation*, *19*(2), 112–125.

Dove Medical Press. (2026). *Artificial intelligence for cardiovascular risk prediction: An umbrella review of applications and translational challenges*.

Dredge, K., Marriott, J. B., Macdonald, C. D., et al. (2002). Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. *British Journal of Cancer*, *87*(10), 1166–1172. https://doi.org/10.1038/sj.bjc.6600607

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., ... & Hyman, D. M. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *The New England Journal of Medicine*, *378*(8), 731–739.

DrugPatentWatch. (2026). *The orphan drug paradox: Navigating high-margin entry and AI R&D cost reduction*.

Drummond, M., Neumann, P. J., & Sullivan, S. D. (2024). The economics of curative gene therapies: Payment models and health technology assessment. *Value in Health*, *27*(1), 15–22.

Durvasula, M. M., Eyuboglu, S., & Ritzwoller, D. M. (2024). Counting clinical trials: New evidence on pharmaceutical sector productivity. *arXiv*. https://doi.org/10.48550/arxiv.2405.08030

Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Central Science*, *6*(5), 672–683.

Eccles, R. G., Ioannou, I., & Serafeim, G. (2014). The impact of corporate sustainability on organizational processes and performance. *Management Science*, *60*(11), 2835–2857.

Eichler, H. G., Baird, L. G., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., ... & Hirsch, G. (2016). From adaptive pathway to adaptive pharmacoeconomics? *Clinical Pharmacology & Therapeutics*, *100*(4), 434–436.

Epthinktank. (2026). *Regulatory sandboxes under the EU AI act: Implications for healthcare and life sciences*.

European Commission. (2023). *Proposal for a directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/120/EC*. Brussels.

European Federation of Pharmaceutical Industries and Associations. (2026). *Governance as a design constraint in digital health and AI ecosystems*.

European Medicines Agency. (2018). *Guideline on the environmental risk assessment of medicinal products for human use*. Committee for Medicinal Products for Human Use (CHMP).

Farrukh, A., & Sajjad, A. (2023). Managing paradoxical tensions in corporate sustainability. *International Journal of Sustainable Development & World Ecology*, *30*(2), 125–139.

Fidler, B. (2025). Novartis dives deeper into protein degraders with second Monte Rosa deal. *BioPharma Dive*.

Fontrier, A. M., Gill, J., & Kanavos, P. (2019). International pricing of medicines: The impact of external reference pricing on drug availability and affordability. *Expert Review of Pharmacoeconomics & Outcomes Research*, *19*(3), 283–294.

Food and Drug Administration. (2022a). *Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry*. U.S. Department of Health and Human Services.

Food and Drug Administration. (2022b). *FDA approves first gene therapy to treat adults with hemophilia B*. U.S. Department of Health and Human Services.

Franco, P. (2013). Orphan drugs: The regulatory environment. *Drug Discovery Today*, *18*(3-4), 163–172.

Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., ... & Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *The New England Journal of Medicine*, *384*(3), 252–260.

Franklin, J. M., Glynn, R. J., Martin, D., & Schneeweiss, S. (2019). Evaluating the use of nonrandomized real-world data analyses for regulatory decision making. *Clinical Pharmacology & Therapeutics*, *105*(4), 867–877.

Frontiers in Digital Health. (2025). *The data dossier: Validating meaningful aspects of health via patient experience data*.

Gammie, T., Lu, C. Y., & Babar, Z. U. D. (2015). Access to orphan drugs: A comprehensive review of legislations, regulations and policies. *Drugs*, *75*(20), 2365–2377.

Garnier, J. P. (2008). Rebuilding the R&D engine in big pharma. *Harvard Business Review*, *86*(5), 68–76.

Garrison, L. P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P. E., ... & Molsen, E. (2015). Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force Report. *Value in Health*, *18*(5), 703–719.

Gautam, A., & Pan, X. (2016). The changing model of big pharma: Impact of key trends. *Drug Discovery Today*, *21*(3), 379–384. https://doi.org/10.1016/j.drudis.2015.10.002

Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006). Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. *Nature Reviews Drug Discovery*, *5*(8), 689–702.

Giarratana, M. S., & Santaló, J. (2020). *Multi-niche firms and resource redeployment: Transaction costs in shelf-dominated sectors*. Mack Institute for Innovation Management, Wharton School.

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O'Connell, D., Walsh, K. R., Wood, K., Phillips, J., Fowles, A., Forte, E., Makrogiannis, V., Macauley, P., Xu, X., Zhang, H., Wu, F., Jiang, Y., … & Sepp-Lorenzino, L. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. *The New England Journal of Medicine*, *385*(6), 493–502. https://doi.org/10.1056/NEJMoa2107454

Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., ... & Topp, M. S. (2016). Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. *Blood Cancer Journal*, *6*(9), e473.

Goldsack, J. C., Coravos, A., Bakker, J. P., Bent, B., Dowling, A. V., Fitzer-Attas, C., ... & Wood, W. A. (2019). Digital health metrics and biomarkers: Defining the terms. *npj Digital Medicine*, *2*(1), 1–5.

Grabowski, H. G., Long, G., & Mortimer, R. (2012). Recent trends in orphan drug development. *Pharmacoeconomics*, *30*(4), 281–294.

Grabowski, H., & Long, G. (2011). The role of biosimilars in the pharmaceutical market: Policy and commercial implications. *Nature Reviews Drug Discovery*, *10*(6), 434–440.

Gropman, A., & Komor, A. (2025). Personalized gene editing to treat an inborn error of metabolism. *The New England Journal of Medicine*, *390*(20), 15–18. https://doi.org/10.1056/NEJMe2505721

Hagemann, J., et al. (2023). The clinical impact of radioligand therapy supply shortages: Lessons from the commercialization of Lutetium-177 PSMA. *European Journal of Nuclear Medicine and Molecular Imaging*, *50*(8), 2210–2215.

Healthcare Digital. (2026). *Microsoft & Novo Nordisk: Accelerating pharma R&D with AI.*

Heine, R. J. S. D., Thielen, F. W., Mathijssen, R. H. J., van Leeuwen, R. W. F., Franken, M. G., & Uyl-de Groot, C. A. (2024). Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. *PLOS ONE*, *19*(8), e0293264. https://doi.org/10.1371/journal.pone.0293264

Heinrich, M., & Lang, K. (2023). Digital product passports: Enablers of a circular economy. *Circular Economy and Sustainability*, *3*(2), 1–18.

Horgan, D., Koeva-Balabanova, J., Capoluongo, E., Jagielska, B., Cattaneo, I., Kozaric, M., Tumiene, B., El Ahl, J.-P., Lal, J. A., Kalra, D., & Malats, N. (2022). Making sure that orphan incentives tip the right way in Europe. *Healthcare*, *10*(9), 1600. https://doi.org/10.3390/healthcare10091600

Hwang, T. J., Bourgeois, F. T., & Kesselheim, A. S. (2019). Analysis of the US Food and Drug Administration's pediatric rare disease priority review voucher program. *JAMA*, *321*(8), 796–798.

Iansiti, M., & Lakhani, K. R. (2020). *Competing in the age of AI: Strategy and leadership when algorithms and networks run the world*. Harvard Business Review Press.

IntuitionLabs. (2026a). *Big pharma & hyperscaler AI deals: 2026 industry tracker*.

IntuitionLabs. (2026b). *Pharma AI strategy: Scaling digital transformation and hyperscaler alliances*. IntuitionLabs Research.

IQVIA. (2024). *The global use of medicines: Demand and spending outlook*. IQVIA Institute for Human Data Science.

IQVIA. (2025). *Global trends in R&D: Reducing trial complexity and time-to-market through predictive modeling*.

Jayatunga, M. K., Xie, W., Ruder, L., Schulze, U., & Meier, C. (2022). AI in small-molecule drug discovery: A coming of age? *Nature Reviews Drug Discovery*, *21*(3), 175–176.

Jin, Q., Wang, Z., Floudas, C. S., Chen, F., Gong, C., Bracken-Clarke, D., Xue, E., Yang, Y., Sun, J., & Lu, Z. (2023). Matching patients to clinical trials with large language models. *arXiv*. https://doi.org/10.1038/s41467-024-53081-z

Jørgensen, J. T. (2011). Bye, bye blockbusters, hello niche busters. *Expert Review of Molecular Diagnostics*, *11*(6), 557–559.

Jørgensen, J., Hanna, E., & Kefalas, P. (2024). Advanced therapy medicinal products (ATMPs): Supply chain logistics and commercialization challenges in the European market. *Journal of Market Access & Health Policy*, *12*(1), 210–219.

Kaitin, K. I. (2010). Deconstructing the drug development process: The new face of innovation. *Clinical Pharmacology & Therapeutics*, *87*(3), 356–361.

Kaló, Z., Niewada, M., Bereczky, T., et al. (2023). Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries. *Expert Review of Pharmacoeconomics & Outcomes Research*, *24*, 181–187. https://doi.org/10.1080/14737167.2023.2282680

Kantarjian, H., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. *Blood, The Journal of the American Society of Hematology*, *121*(22), 4439–4442.

Kirzner, I. M. (1997). Entrepreneurial discovery and the competitive market process: An Austrian approach. *Journal of Economic Literature*, *35*(1), 60–85.

Knepper, T. C., & McLeod, H. L. (2018). When will clinical trials reflect diversity? *Nature*, *557*(7704), 157–159.

Knight, F. H. (1921). *Risk, uncertainty and profit*. Houghton Mifflin.

Krka. (2026). *ESG-driven capital expenditure in the pharmaceutical supply chain*.

Labbé, M., Toumi, M., & The ISPOR Rare Disease Special Interest Group. (2020). Market access and health technology assessment of orphan drugs in Europe: Past, present, and future. *Value in Health*, *23*(1), 16–24.

Lactalis. (2026). *Operationalizing the green transition: Energy and water reductions in continuous manufacturing*.

Li, X., Chowdhury, S., Wi, C. I., Vassilaki, M., Liu, X., Sio, T. T., Garrick, O., Juhn, Y. J., Cerhan, J. R., Tao, C., & Zong, N. (2025). LLM-Match: An open-sourced patient

matching model based on large language models and retrieval-augmented generation. *arXiv*. https://doi.org/10.48550/arxiv.2503.13281

Liao, K.-H., Ko, B.-S., Chen, L.-K., & Hsiao, F.-Y. (2020). Factors affecting usage levels and trends of innovative oncology drugs upon and after reimbursement under Taiwan National Health Insurance: Interrupted time series analysis. *Clinical and Translational Science*, *13*(6), 1288–1297. https://doi.org/10.1111/cts.12829

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. *The New England Journal of Medicine*, *389*(24), 2221–2232.

Linker, R. A., & Gold, R. (2013). Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects. *Current Neurology and Neuroscience Reports*, *13*(11), 394.

Lovly, C. M., & Shaw, A. T. (2014). Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. *Clinical Cancer Research*, *20*(9), 2249–2256.

Lu, X., Yang, C., Liang, L., Hu, G., Zhong, Z., & Jiang, Z. (2024). Artificial intelligence for optimizing recruitment and retention in clinical trials: A scoping review. *Journal of the American Medical Informatics Association*, *31*(11), 2749–2759. https://doi.org/10.1093/jamia/ocae243

Lubkeman, M., et al. (2021). *Externalization in biopharma: Business development as a core competency*.

Luzzatto, L., Hyry, H. I., Schieppati, A., Costa, E., Simoens, S., Schaefer, F., & Garattini, S. (2018). Outrageous prices of orphan drugs: A call for collaboration. *The Lancet*, *392*(10149), 791–794.

Main, C., Schäfer, C., & Kanavos, P. (2025). From vision to reality: The EU's pharmaceutical reforms and the path to improved access. *PharmacoEconomics - Open*. https://doi.org/10.1007/s41669-024-00556-w

Michel, M., & Toumi, M. (2012). Access to orphan drugs in Europe: Current and future prospects. *Expert Review of Pharmacoeconomics & Outcomes Research*, *12*(1), 43–49.

Microsoft. (2026). *Novo Nordisk accelerates clinical insight with custom agents on Azure*.

Miksad, R. W., & Abernethy, A. P. (2018). Harnessing the power of real-world evidence in oncology. *Clinical Pharmacology & Therapeutics*, *103*(2), 202–209.

Mökander, J., Schuett, J., Kirk, H. R., & Floridi, L. (2022). Auditing large language models: A three-layered approach. *AI and Ethics*, *2*(4), 481–501.

Monte Rosa Therapeutics. (2025). *Monte Rosa announces collaboration with Novartis for degraders to treat immune-mediated diseases*. GlobeNewswire.

Mrowietz, U., Asadullah, K., & Meier, M. (2007). Formulations of fumaric acid esters in the treatment of psoriasis. *American Journal of Clinical Dermatology*, *8*(4), 207–214.

Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022). Anti-obesity drug discovery: Advances and challenges. *Nature Reviews Drug Discovery*, *21*(3), 201–223.

Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. *Nature Reviews Drug Discovery*, *8*(12), 959–968.

Musunuru, K. (2023). In vivo CRISPR base editing for cardiovascular disease. *Nature Cardiovascular Research*, *2*(6), 524–535. https://doi.org/10.1038/s44161-023-00276-8

Musunuru, K., Grandinette, S. A., Wang, X., Ahrens-Nicklas, R., & CHOP-Penn Clinical Team. (2025). Patient-specific in vivo gene editing to treat a rare genetic disease. *The New England Journal of Medicine*, *390*(20), 1–9. https://doi.org/10.1056/NEJMoa2504747

Nakashima, T., et al. (2023). *Regional focus and inter-regional alliances: Growth models for specialized pharmaceutical companies*.

Narrativa. (2026). *Executing R&D tasks: The transition to agentic AI in regulatory submissions*.

National Health Service England. (2023). *Delivering a 'net zero' National Health Service: The NHS supplier roadmap*. NHS England Procurement Guidelines.

Ng, A., Offensperger, F., Cisneros, J. A., Scholes, N. S., Malik, M., Villanti, L., Rukavina, A., Ferrada, E., Hannich, J. T., Koren, A., Kubicek, S., Superti-Furga, G., & Winter, G. E. (2023). Discovery of molecular glue degraders via isogenic morphological profiling. *ACS Chemical Biology*, *18*(11), 2464–2473. https://doi.org/10.1021/acschembio.3c00598

Olson, M., & Capkun, G. (2024). The value of evidence and its role in driving product strategy. *Journal of Comparative Effectiveness Research*, *13*. https://doi.org/10.57264/cer-2024-0074

O'Reilly, C. A., & Tushman, M. L. (2013). Organizational ambidexterity: Past, present, and future. *Academy of Management Perspectives*, *27*(4), 324–338.

PackGene Biotech. (2026). *2025's most impactful cell and gene therapy milestones*.

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. *Nature Reviews Drug Discovery*, *10*(6), 428–438.

Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. *Nature Reviews Neurology*, *15*(2), 73–88.

Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today*, *26*(1), 80–93. https://doi.org/10.1016/j.drudis.2020.10.010

Pharma Focus Europe. (2026). *Sustainability as a legal mandate for European market access*.

Pharmaceutical Technology. (2024). *Rare disease assets hedge against portfolio risk and stabilize long-term portfolio value potential*. Pharmaceutical Technology Business Insights.

Porter, M. E., & Kramer, M. R. (2006). Strategy and society: The link between competitive advantage and corporate social responsibility. *Harvard Business Review*, *84*(12), 78–92.

PubMed Central. (2026). *Data-maturity bridges and the FAIR principle in biotech alliances*.

Pushpakom, S., Iorio, F., Eyers, P. A., Escullier, K. J., Blanco, G., Cox, T., ... & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. *Nature Reviews Drug Discovery*, *18*(1), 41–58.

PwC. (2026). *The AI-enabled enterprise: Digital twins and computational capital in the life sciences*.

Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., & Xu, Q. (2021). Lipid nanoparticle-mediated codelivery of Cas9 mRNA and sgRNA

achieves systemic and tissue-specific genome editing in vivo. *Gene Therapy*, *28*(3-4), 143–150. https://doi.org/10.1038/s41434-020-00196-1

Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., ... & Rowe, S. M. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *The New England Journal of Medicine*, *365*(18), 1663–1672.

Rasmussen, B., & Foss, N. J. (2014). Business model innovation in the pharmaceutical industry: The core mechanism of value capture. *Journal of Business Models*, *2*(1).

Resnik, D. B., & Shamoo, A. E. (2016). Reproducibility and research integrity. *Accountability in Research*, *24*(2), 116–123. https://doi.org/10.1080/08989621.2016.1257387

Rintoul, A., Colbert, A., Garner, S., et al. (2020). Medicines with one seller and many buyers: Strategies to increase the power of the payer. *BMJ*. https://doi.org/10.1136/bmj.m1705

Rome, B. N., Lee, C. C., & Kesselheim, A. S. (2021). Market exclusivity length for drugs with multiple approved indications. *JAMA Network Open*, *4*(3), e213435.

Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z. F., Tillman, A., ... & Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. *The Lancet*, *390*(10097), 849–860.

Sasso, J. M., Tenchov, R., Wang, D., Johnson, L. S., Wang, X., & Zhou, Q. A. (2022). Molecular glues: The adhesive connecting targeted protein degradation to the clinic. *Biochemistry*, *62*(1), 601–623. https://doi.org/10.1021/acs.biochem.2c00245

Scannell, J. W., & Bosley, J. (2016). When quality beats quantity: Decision theory, drug discovery, and the reproducibility crisis. *PLOS ONE*, *11*(2), e0147215. https://doi.org/10.1371/journal.pone.0147215

Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature Reviews Drug Discovery*, *11*(3), 191–200. https://doi.org/10.1038/nrd3681

Schaber, S. D., Gerogiorgis, D. I., Ramachandran, R., Evans, J. M., Barton, P. I., & Trout, B. L. (2011). Economic analysis of integrated continuous and batch pharmaceutical manufacturing: A case study. *Industrial & Engineering Chemistry Research*, *50*(17), 10083–10092.

Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. *Journal of Translational Medicine*, *14*(1), 105.

Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020). Radiopharmaceutical therapy in cancer: Clinical advances and challenges. *Nature Reviews Drug Discovery*, *19*(9), 589–608.

Shih, W. C. (2020). Global supply chains in a post-pandemic world. *Harvard Business Review*, *98*(5), 82–89.

Shih, W. C., & Pisano, G. P. (2024). The new vulnerabilities of global pharmaceutical supply chains: Lessons from the obesity drug boom. *Harvard Business Review*.

Song, C. H., & Lee, J. (2016). Strategic switch and lifecycle management: Navigating the pharmaceutical patent cliff. *Drug Discovery Today*, *21*(3), 473–479. https://doi.org/10.1016/j.drudis.2015.12.007

Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? *Nature Reviews Drug Discovery*, *10*(7), 507–519.

Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008). HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. *Cell Metabolism*, *7*(5), 365–375.

Teece, D. J. (2007). Explicating dynamic capabilities: The nature and microfoundations of (sustainable) enterprise performance. *Strategic Management Journal*, *28*(13), 1319–1350.

Teece, D. J. (2010). Business models, business strategy and innovation. *Long Range Planning*, *43*(2-3), 172–194.

Teece, D. J. (2018). Business models and dynamic capabilities. *Long Range Planning*, *51*(1), 40–49.

Tennison, I., Roschnik, S., Ashby, B., Boyd, R., ... & Pencheon, D. (2021). Health care's response to climate change: A carbon footprint assessment of the NHS in England. *The Lancet Planetary Health*, *5*(2), e84–e92.

Terranova, N., & Venkatakrishnan, K. (2024). Machine learning in modeling disease trajectory and treatment outcomes: An emerging enabler for model-informed precision medicine. *Clinical Pharmacology & Therapeutics*, *115*(4), 720–726. https://doi.org/10.1002/cpt.3153

TS Quality & Engineering. (2026). *In silico validation: Digital twins in pharmaceutical scale-up and manufacturing*.

Tucker, J. (2023). The GLP-1 supply crisis: When demand outpaces global manufacturing capacity. *PharmaEconomics Review*, *14*(4), 88–102.

Vallano, A., et al. (2024). Value-based contracting and performance agreements in a constrained healthcare economy. *Health Policy*, *140*, 10–18.

Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, *18*(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Kramer, L. D. (2023). Lecanemab in early Alzheimer's disease. *The New England Journal of Medicine*, *388*(1), 9–21.

Viceconti, M., Pappalardo, F., Rodriguez, B., Horner, M., Bischoff, J., & Musuamba Tshinanu, F. (2021). In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. *Methods*, *185*, 120–127. https://doi.org/10.1016/j.ymeth.2020.01.011

Visnjic, I., Wiengarten, F., & Neely, A. (2016). Only the brave: Product innovation, service business model innovation, and their impact on performance. *Journal of Product Innovation Management*, *33*(1), 36–52.

Vokinger, K. N., & Gasser, U. (2021). Regulating AI in medicine in the United States and Europe. *Nature Machine Intelligence*, *3*(9), 738–739.

Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., ... & Weir, C. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nature Reviews Drug Discovery*, *14*(7), 475–486.

Wedam, L., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., ... & Pazdur, R. (2020). FDA approval summary: Palbociclib for male patients with metastatic breast cancer. *Clinical Cancer Research*, *26*(5), 1208–1212.

Wellman-Labadie, O., & Zhou, Y. (2010). The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? *Health Policy*, *95*(2-3), 216–228.

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. *The New England Journal of Medicine*, *384*(11), 989–1002.

Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., ... & Mons, B. (2016). The FAIR Guiding Principles for scientific data management and stewardship. *Scientific Data*, *3*(1), 1–9. https://doi.org/10.1038/sdata.2016.18

Woodcock, J., & LaVange, L. M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. *The New England Journal of Medicine*, *377*(1), 62–70.

Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. *JAMA*, *323*(9), 844–853.

Zemplenyi, A., Leonard, J., DiStefano, M. J., Anderson, K. E., Wright, G. C., Mendola, N. D., Nair, K., & McQueen, R. B. (2023). Using real-world data to inform value-based contracts for cell and gene therapies in Medicaid. *PharmacoEconomics*, *42*, 319–328. https://doi.org/10.1007/s40273-023-01335-x

Zott, C., & Amit, R. (2008). The fit between product market strategy and business model: Implications for firm performance. *Strategic Management Journal*, *29*(1), 1–26.

Appendix A: "Title of appendix"

…

…

Appendix B: "Title of appendix"

…

…

Author's Statement:

I hereby expressly declare that, according to the article 8 of Law 1559/1986, this dissertation is solely the product of my personal work, does not infringe any intellectual property, personality and personal data rights of third parties, does not contain works/contributions from third parties for which the permission of the authors/beneficiaries is required, is not the product of partial or total plagiarism, and that the sources used are limited to the literature references alone and meet the rules of scientific citations.